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ABSTRACT
CHEMICAL, BIOLOGICAL AND PRELIMINARY IN VITRO STUDIES OF NOVEL
VANADIUM(IV) COMPLEXES WITH SCHIFF BASES AND
THIOSEMICARBAZONE LIGANDS
by Nerissa Lewis
December 2011
9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-L-tryp)]
and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff
base) were prepared using known synthetic procedures. Two novel thiosemicarbazone
ligands, (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (NEthhymethohcarbthio) and (E)-N-ethyl-2-(1-(thiazol-2yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands
were characterized by FT IR and electrochemistry. N-Ethhymethohcarbthio were
characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-L-tryp)]
were characterized by ESI MS. X-ray crystallography was also used to characterize
acetylethTSC. The ligands were then reacted with [VO(Sal-L-tryp)(H2O)] (1) (Sal-L-tryp
= N-salicylidene-L-tryptophanate) to produce the novel complexes, [VO(Sal-Ltryp)(MeATSC)].1.5C2H5OH (2), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (3),
and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH (4), respectively. All complexes were
characterized by elemental analysis, ESI MS, IR, UV-visible, 1H and 13C NMR
spectroscopy, and electrochemistry. Oxidized DMSO and DMSO-d6 solutions of each
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complex were also characterized by ESI MS and 1H NMR spectroscopy. [VO(Sal-Ltryp)(MeATSC)].1.5C2H5OH, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O, and
[VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative
activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. When the
anti-proliferative effects were compared with that of non-cancerous colonic
myofibroblasts, less inhibition was observed. The results obtained suggest that these
compounds can be used as potential chemotherapeutic agents.
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CHAPTER I
INTRODUCTION
Vanadium History
Vanadium was first discovered by the Spanish-Mexican mineralogist Andrés del
Río in the year 1813.1,2 The element was given the name vanadium, after Vanadis, the
Norse goddess of love and beauty (Figure 1), due to the variety of colors formed in
solution upon changes in concentration and pH.1-3 Vanadium is therefore the only
element in the periodic table that is named after a goddess.4

Figure 1. A painting of “Vanadis” the Norse goddess of love and beauty.5
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Vanadium is a widely dispersed element found at generally low concentrations in
approximately 65 minerals including patronite (VS4), vanadinite (Pb5(VO4)3Cl) and
carnotite (K2(UO2)2(VO4)2.3H2O).6 As a trace element, vanadium is known to occur at
extremely low concentrations in mammalian tissues and is essential for many mammalian
species distributed on earth.3,7,8 Although the exact function of this element remains
unclear, vanadium is known to be beneficial and possibly essential for humans and some
living organisms.3,9-13
Vanadium Chemistry
Vanadium is the 23rd element of the periodic table and is known to possess
numerous chemical and biochemical properties.3,4,7 Vanadium, a typical first row
transition metal, is a silvery grey metal which has an electronic configuration of [Ar]
3d34s2.14,15 Vanadium displays a wide variety of oxidation states and varying geometries
(Table 1).4,7,16 The most common oxidation states of vanadium are V2+, V3+, V4+ and V5+
for which the corresponding electronic configurations are [Ar] 3d3, [Ar] 3d2, [Ar] 3d1 and
[Ar] 3d0, respectively.14 Given the varying possible oxidation states of vanadium, the
partial pressure of oxygen p[O2] is a very strong factor for reactions involving
vanadium.14 In aqueous solutions, (V(III)) is the lowest oxidation state of vanadium that
is relatively stable.3
The aqueous chemistry of V(II) are very sparse in literature. The most commonly
mentioned aqua V(II) species is the [V(H2O)6]2+ as shown in Table 1. The aqueous
chemistry of V(III) has been studied to a much lesser extent than that of V(IV) and
V(V).3,17-20 V(III) complexes are known to form numerous mononuclear, binuclear, and
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Table 1
Variety of oxidation states and geometries exhibited by vanadium.16

Oxidation
State

Coordination
number

V-1, d6
V0, d5
V1, d4

6
6
6

Geometry

Examples
V(CO)-6, Li[V(bipy)3].4C4H8O
V(CO)-6, V(bipy)3, V[C2H4(PMe2)2]3
[V(bipy)3]+
5
-C5H5V(CO)4
[V[(CO)3(PMe3)4]+, V(CO)2(dmpe)2Cl

7

Octahedral
Octahedral
Octahedral
Tetragonal pyramidal
Monocapped octahedral

4

Almost planar

5
6a

Sp
Octahedral

VIII, d2

3
4
5
6a
7

Planar
Tetrahedral
tbq
Octahedral
Pentagonal bipyramidal

VIV, d1

4
5

6

Tetrahedral
Tetragonal pyramidal
sp
tbp
Octahedral

8

Dodecahedral

4
5

Tetrahedral
tbp
sp

VOCl3
VF5(g), VNCl2(quinuclidine)2
CsVOF4

6a

Octahedral

VF5(s), VF6-, V2O5, [VO2(ox)2]3-,V2S5

7

Pentagonal bipyramidal

VII, d3

VV, d0

[Li(THF)]2V(2,6diisopropylphenolate)4]
(2,6-Ph2C6H3O)2V(py)3
[V(H2O)6]2+, [V(CN)6]4V[N(SiMe3)2]3, V[CH(SiMe3)3]3
[VCl4]trans-VCl3(SMe2)2, VCl3(NMe3)2
[V(NH3)6]3+, [V(C2O4)]3-, VF
K4[V(CN)7].2H2O

VCl4, V(NEt2)4, V(CH2SiMe3)4
VO(acac)2, PCl4+VCl5[V2O4(OH)2(PhPO3)4]2+
VOCl2 trans-(NMe3)2
VO2(rutile), K2VCl6, VO(acac)2(py),
VO(acac)2Cl2
VCl4(diars)2, V(S2CMe)4

VO(NO3)3.CH3CN, VO(Et2NCS2)3

4
species of high nuclearities which introduces ambiguity when attempting to identify the
actual species that is present in solution.21
Due to the presence of unpaired electrons, vanadium compounds of lower
oxidation states are paramagnetic in nature and generally exist as colored compounds.22
V(III) complexes are therefore NMR silent, leading to further complications in the
analysis of the species present in solution.21 V(III) solutions are also easily oxidized (E0 =
+0.34 V (vs NHE)) (Equation 1)23 and therefore requires stringent anaerobic conditions
during speciation studies.3

VO2+ + 2H+ + 2e-

V3+ + H2O

……………….. (1)

V(III) compounds therefore require strongly acidic conditions or the presence of a potent
chelator in order to exist in aqueous solutions.3 These compounds generally form
octahedral complexes, such as [V(H2O)6]3+, [VCl2(MeOH)4]+, [V(NCS)6]3-, and
[VCl2(THF)2(H2O)2]+.3,24
The aqua V(III) ion, [V(H2O)6]3+, is greenish blue in color and is mainly obtained
from electrolytic or chemical reduction of V(IV) and V(V).3 Under strongly acidic
conditions, V(III) ions predominate as [V(H2O)6]3+ ions (at pH < 1) and as
[V(OH)(H2O)5]2+ ions (at pH = 1.0 - 3.5) (Figure 2).3 As the pH increases further (1.0 <
pH < 3.5), V(III) ions undergo dimerization to form [V2( 2-O)(H2O)10]4+ (Figure 2).3,18
Upon further increase in pH, the trinuclear [V3(OH)8(H2O)10]+ and tetranuclear
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Figure 2. Polymeric V(III) species.3
[V4(OH)12(H2O)12] species are formed at pH > 3.5 (Figure 2).3,18 As the pH exceeds a
value of 4.5 (pH > 4.5), an insoluble solid usually referred to as (V(OH)3)n then begins to
form in solution which emphasizes the need for a strong chelation to remove soluble
V(III) that may still be present at neutral pH.3,25,26
V(IV) complexes are paramagnetic in nature and generally forms compounds that
are colorless, pale yellow or red in color.22 V(IV) compounds exists primarily in a square
pyramidal or peuedo-octahedral coordination, as the hydrated vanadyl cation,
[VO(H2O)5]2+ (VO2+) (Figure 3).3,27 The vanadyl cation, formed by dissolving VOSO4

Figure 3. Structure of the most common vanadyl cation.3
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in acidic aqueous solutions, is probably the most stable diatomic ion and is known to be
present in approximately 98% of all V(IV) solid compounds and aqueous solutions.24,27-29
The VO2+ cation is known to form many complexes and the identity of this ion is
retained throughout a wide variety of reactions.24 This cation is very stable under acidic
conditions and is the main species present in solution at pH 3.3,30 As the pH is increased
into the physiological range, several oligomeric and polymeric spin-paired species are
then formed.27 The speciation of V(IV) species at nanomolar to submicromolar and at
millimolar concentrations of V(IV) is shown in Schemes 1 and 2, respectively.3 As
shown in Schemes 1 and 2, as pH increases (pH ~ 4), a proton is loss resulting in the
formation of the hydrolyzed species, [VO(H2O)4(OH)]+ species.3

Scheme 1. Aqueous [VO(OH2)5]2+ Hydrolysis Products at Nano to Submicromolar
Concentrations of V(IV).3 The insoluble hydroxide VO(OH)2 n is in equilibrium with
the positively and negatively charged monomeric species.

Scheme 2. Aqueous [VO(OH2)5]2+ Hydrolysis Products at Micro to Millimolar
Concentrations of V(IV).3
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As the pH increases further (pH>5), an insoluble VO(OH)2

n

species is formed,

which dissolves to form a binuclear species ([(VO)2(OH)5]-), and a subsequent
monomeric species [VO(OH)3]- upon further increase in pH.3,31 In the speciation diagram
(Figure 4), the existence of negatively charged monomeric V(IV) species at neutral pH is
clearly illustrated.3 Figure 4 displays a diagram of the V(IV) species that generally exist
in aqueous solutions.3 Extensive studies have been carried out on the aqueous chemistry
of V(V) ions, which are readily solvated in aqueous solutions to form the hydrated
[V(OH2)n]5+ species.32 According to thermodynamic evidence, when compared with

Figure 4. Predominance area diagram for aqueous V(IV) species, which is represented as
the logarithm of the total molar concentration of vanadium(IV) against pH. Solid lines
represent the condition where the concentrations of two soluble species in equilibrium.3
“Reprinted with permission from Crans, D. C.; Smee, J. J.; Gaidamauskas, E.; Yang, L.
Chem. Rev. 2004, 104, 849. Copyright 2004 by the American Chemical Society.”
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H3VO4, the high stability of the vanadate ion (VO4+) is often accounted for by an increase
in coordination number.3,33 The pH of the solution and the concentration of the vanadium
oxide are two critical factors for determining the identity of the specific vanadium oxide
present in aqueous solution.7,15 V(V) readily hydrolyzes to form twelve different species
consisting of both monomeric and polymeric species.15,34 The strong polarizing power of
the V(V) ion leads to an increase in the acidity solutions due to the partial dissociation of
coordinated water molecules (Equation 2).32

[VV(OH2)6]5+ + nH2O

[VV(OH)n(OH2)6-n](5-n)+ + nH3O+ .………...

(2)

The existence of various oxides of vanadium at varying pH is illustrated in the
Pourbaix diagram shown in Figure 5.30 The Pourbaix diagram clearly indicates the
existence of V(V) species at higher pH and the subsequent existence of V(IV) species at
low pH.3,35,36 In Figures 5a and 5b, it is also observed that vanadium exists mainly as
cationic species at pH < 3, and as anionic species pH > 3.5.30 In aqueous solutions, the
decameric species, [V10O28]6-, and its protonated forms are the major V(V) species
present.3,37 Due to the instability of this compound, [V10O28]6- often serves as a
thermodynamic sink in solutions at pH = 3-6.3,37
V(V) compounds generally forms a variety of polyoxoanions and may exist in a
tetrahedral (VO4), pentahedral (VO5) or octahedral (VO6) coordination environments.3 At
physiological pH, the vanadate mononuclear species exists predominantly in the
monomeric form as the H2VO4- ion.3,27,38,39 In the presence of nucleophillic ligands,

9

Figure 5. Potential–pH diagrams for the vanadium–water system at 298.15 K: (a)
activities of dissolved vanadium of 10-2 and (b) activities of dissolved vanadium of 10-6.30
Reproduced with permission from Hydrometallurgy 2011, 106,105. Copyright 2011 by
Elsevier.
monomeric vanadate readily undergoes various condensation reactions to form numerous
species in solution (Figure 6).3
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Figure 6. Structures of the major deprotonated oxovanadium(V) ions.3,41,42
Vanadium pentoxide (V2O5) is amphoteric in nature and readily dissolves in
strong aqueous alkali to form colorless solutions, consisting mainly of VO43-.40 As the
acidity of the solution is increased, the colorless solution deepens in color, and changes
from orange to red (just below neutral pH).40 As the acidity is further increased, a
brown precipitate of V2O5 is formed, which readily dissolves at lower pH to give a paleyellow solution.40 The existence of various vanadate species in aqueous solutions is
dependent on the pH and total concentration of vanadium in solution.40 The predominant
oligomer formed under acidic conditions (2 ≤ pH ≤ 6) is the yellow-orange
decavanadate ion [V10O28]6- (V10) which is capable of existing in several protonated
forms (Scheme 3).16 Upon further addition of acid, the [V10O28]6- readily forms the
dioxovanadium(V) ion (VO2+).16 The main oligomeric species present from pH 6 to 10
includes the dimeric [V2O7]4- ion (V2), the cyclic tetrameric [V4O12]4- ion (V4), and the
cyclic pentameric [V5O15]4- ion (V5), which are all colorless.27,43,44
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Scheme 3. Protonated forms of decavanadate ion.16
Schiff Base Complexes of Vanadium
Schiff bases are considered to be a very important class of compounds that are
widely used due to their good solubility properties and their remarkable versatility.45
Schiff bases and their metal complexes are known to exhibit a broad variety of biological
activity such as anti-viral,46 anti-parasitic,47 anti-bacterial,48 anti-inflammatory,49 antitumor,50,51 anti-HIV,52 anti-cancer,53 etc.
According to Sen et al.,54 metal complexes containing salen-type Schiff bases
are capable of exhibiting unusual coordination, high thermodynamic stability and kinetic
inertness.54 Schiff bases display interesting asymmetric catalytic activity, and their metal
complexes are of great interest as enzyme models since they are capable of mimicking
biological sites.54
Recently, the use of heterogenized VIVO and VVO2 complexes as catalysts for the
functionalization of alkenes were reported by Maurya et al.55 Previously, the
encapsulation of [VVO2(Sal-aebmz)] (Hsal-aebmz = Schiff base derived from
salicylaldehyde and 2-aminoethylbenzimidazole) in zeolite-Y (where the zeolite acts as a
protein mantle) was shown to significantly improve the catalytic activity of the zeolite by
yielding a higher turnover frequency. This catalyst (or catalyst precursor) was also found
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to be easily recyclable and maintain their activity for several cycles of catalytic use.55 In
their present study, the catalytic activity of similar VIVO and VVO2 complexes containing
ligands 10 (Hpydx-aebmz) and 11 (Hpydx-ambmz) (Figure 7) were also investigated.55

Figure 7. Structural formula of Schiff base ligands used for catalytic activity.55
Similarly, both complexes exhibited similar catalytic properties when compared to that of
[VVO2(Sal-aebmz)].55
Extensive research has been carried out on complexes of N-salicylideneamino
acids, typified by their vanadium compounds.56-59 V(IV) and V(V) complexes containing
Schiff base ligands generally exhibit coordination geometry such as that of compounds
12 and 13 shown in Figure 8. The formation of dinuclear oxo-bridged VIV–O–VV or VV–
O–V compounds (such as compound 14 in Figure 8) has also been reported.59-61 When
methanolic solutions of [VIVO(sal–aa)(H2O)] complexes (sal–aa = N-salicylidene-amino
acidato) were allowed to stand in air, the complexes were spontaneously oxidized to form
[VVO(sal–aa)(OMe)(OHMe)] (13). Similarly, the presence of bpy in solution during
aerial oxidation, results in the formation of compound 15, formed from the coordination
of bpy ligand to the [VIVO]2+ metal center.59-61
Due to their potential pharmacological applications, there is now a growing
interest in the chemistry of hydrazine and hydrazone compounds.62 In the past,
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Figure 8. Structure of V(IV) and V(V) complexes containing Schiff base ligands.59
great interest has aroused in the mode of chelation of acid hydrazides R-CO-NH-NH2 and
their corresponding aryolhydrazones R-CO-NH-N=CHR with transition metal ions.62 In
2008, Mishra and Soni reported the synthesis, characterization and biological activity of
VO(II) and Co(II) complexes synthesized from the reaction of methyl isobutyl ketone
with nicotinamide (mna)/2-amino-4-chlorophenol (map) and 2-hydroxy acetophenone
with nicotinamide (han)/isoniazide (hai) (Figure 9).62 The Schiff base ligands and the

Figure 9. The structure of Schiff base ligands containing acid hydrazides and
aryolhydrazones.62
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respective VO(II) and Co(II) complexes (Figure 10) were shown to exhibit significant
antibacterial and antifungal activity.62 Chelation was suggested to have a major effect on
the enhancement or suppression of the biochemical activity since the majority of the
complexes were observed to be more active than their respective Schiff bases.62
Due to the stability of the quinazoline nucleus, quinazolinones are also an
excellent reservoir of bioactive substances.63 4(3H)-quinazolinones is known to

Figure 10. Proposed structures of VO(II) and Co(II) complexes containing Schiff base
ligands.62

15
possess many potential pharmalogical applications.58,59 Hence, there is now a
considerable interest in the chemistry of 4(3H)-quinazolinones.63,64 Studies involving
vanadium chemistry with4-(3H)-quinazolinones ring systems are very scarce in
literature.63 Very recently, Prasad et al.63 reported the synthesis of two newly synthesized
Schiff base ligands (Figure 11), viz., 2-methyl-3-(pyridine-2

Figure 11. The structure of 4(3H)-quinazolinone Schiff base ligands.63
ylmethyleneamine)quinazolin-4(3H)-one and 3-(4-hydroxy-3methoxybenzylideneamino)-2-methylquinazolin-4(3H)-one with 1,10-phenanthroline.
Biological studies carried out by Prasad et al.63 has also demonstrated the ability
of Schiff base ligands to bind to CT-DNA in intercalative mode.63 According to Prasad et
al.,63 oxovanadium(IV) complexes containing the two newly synthesized Schiff base
ligands (Figure 12), can readily bind to CT-DNA in intercalative mode.63 Schiff base
transition metal complexes are currently used in the design and development of synthetic
restriction enzymes, foot printing agents, chemotherapeutic agents, site specific cleavers,
spectroscopic probes, and molecular photo switches.63 The interaction of these Schiff
base-transition metal complexes with nucleic acids is a therefore major area of research
to medicinal chemists.63
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Vanadium and Cancer
Cancer or neoplasia is the term used to define diseases characterized by
uncontrolled proliferation and the spread of abnormal forms of the body cells.65

Figure 12. Oxovanadium(IV) complexes containing two synthesized Schiff base ligands
that can bind to CT-DNA in intercalative mode.63
Neoplastic cells possesses the ability to continually divide and proliferate which leads to
the formation of localized tumors.65 The invasiveness of these cells and the ability to
metastasize, results in the growth of tumors at secondary sites, which undergoes
uncontrolled growth and later spreads throughout the entire body leading to starvation
and death of normal tissue cells.65
Chemotherapeutic cancer treatment involves the use of drugs that are capable of
selectively targeting rapidly proliferating neoplastic cells (in preference to healthy body
cells) used in combination with surgery and/or radiation therapy.66 An in depth
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understanding of the mechanism by which the regulation of cell division and proliferation
is disrupted by neoplastic cells is critical for advances in new cancer treatment.66 The
activity of anticancer drugs is generally exerted by the inhibition of one or more
processes occurring in the normal cell cycle.65
The study of metal containing antitumor agents began in the year 1969 following
the detection of the antitumor properties of cisplatin [cis-diamminedichloroplatinum(II)]
(Figure 13).67 Cisplatin is one of the most successful anticancer drugs and is effective in

Figure 13. Structure of cisplatin.68
the treatment of a variety of cancers (with a cure rate greater than 90% in the case of
testicular cancer).68-70 The clinical success of cisplatin as an antitumor agent is limited by
factors including acquired or intrinsic drug resistance, and the lack of selectivity for
tumor tissues, which leads to severe side effects including renal impairment,
neurotoxicity and cytotoxicity.71,72 The development of non-platinum metal based drugs
has received considerable interest and a few of these compounds are currently in
undergoing clinical studies.73,74 A range of metal complexes, such as gold, iron,
ruthenium, rhodium, palladium, gallium, and tin have demonstrated interesting antitumor
activity but have not yet entered clinical trial.75
In 1983, English et al.76 and Thompson et al.77 discovered that vanadium exerted
an inhibitory effect on the terminal differentiation of murine erythroleukemia cells.78
Dietary administration of ammonium vanadate was shown to inhibit chemically-induced
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mammary carcinogenesis.77,78 Since then, the use of vanadium in the treatment of human
diseases has been widely investigated.79-82
In 1965, the first discovery of the anticancer effect of vanadium salts were
reported by Kieler et al.83 Since then, several studies have been carried out to determine
the biochemical and molecular mechanism underlying the antitumor vanadium salts.7,84,85
Vanadium was shown to be effective in the prevention and/or reduction of chemically
induced preneoplastic and neoplastic development in various target organs.85 The
putative therapeutic effects of vanadium on the growth and metastatic potential of tumor
cells have also been reported in literature.85
Vanadium compounds are capable of exerting anti-carcinogenic effects in several
different ways as shown in Figure 14.7 Although very few vanadium complexes have
been tested for antitumor activity, several peroxovanadium and vanadocene complexes
are known to exert anti-proliferative and proliferative activity on various cell types.78 In
2004, peroxovanadium complexes including potassium bisperoxo(1,10phenanthroline)oxovanadate(V) and potassium bisperoxo(pyridine-2carboxylato)oxovanadate(V) (Figure 15) were shown to reduce proliferative activity of
neuroblastoma NB41 and glioma C6 cell lines.7,86 The biological effect of vanadium in
various cell lines were also enhanced by the concomitant treatment of vanadate(IV) and
peroxide due to the formation of peroxovanadate.78 In vitro studies also demonstrated a
marked increase in protein tyrosine phosphorylation and phosphoinositide breakdown,
combined with the selective inhibition of protein tyrosine phosphatase and
phosphotyrosine phosphatase activities.78 The inhibitory effect of peroxovanadium
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complexes is proposed to be 100-1000 times greater than that of sodium orthovanadate in
vitro.78
Vanadium compounds generally exert their anti-proliferative effects on normal or
malignant cell lines through cell cycle arrest.78 This was demonstrated by Zhang et al.,88

Figure 14. Schematic presentation of the actions, through which the antitumor effects of
vanadium are exerted.7 (PTPs - Protein Tyrosine Phospahatases and PTKs - Protein
Tyrosine Kinases). Reproduced with permission from Crit. Rev. Oncol. Hematol., 2002,
42, p.255. Copyright 2002 by Elsevier.
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Figure 15. Peroxovanadium complexes that exhibit proliferative activity.87
when vanadate was shown to both induce G2/M-phase arrest in p53-deficient mouse
embryo fibroblasts and promote S-phase entry in the corresponding p53 wild-type
cells.78,88 Anti-proliferative and cytotoxic effects of vanadium compounds may also be
exerted via interactions with DNA.7 Vanadocene complexes, including vanadocene
dichloride (Figure 16), are known to interact with the phosphate groups of DNA
nucleotides to form a labile outer sphere complex.7

Figure 16. The structure of vanadocene dichloride.89
Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) ([VO(SO4)(Me2Phen)2]) (metvan) was also recently identified as an active apoptosis inducing agent with
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potent in vitro antitumor activity (Figure 17).79,90-92 Apoptosis (programmed cell death) is
characterized by nuclear fragmentation, membrane blebbing, nuclear and cytoplasmic
condensation, and by the appearance of apoptotic bodies.7,93 Metvan induces apoptosis in
multiple myeloma cell lines, leukemic cell lines, and solid tumor cell lines derived from
breast cancer, glioblastoma, and testicular cancer patients at nanomolar to low
micromolar concentrations.79,90,91 Metvan is highly effective against cisplatin-resistant
ovarian and testicular cancer cell lines and represents the first vanadium complex as a

Figure 17. Structure of Metvan.144
possible alternative to platinum-based chemotherapy.94 Metvan induced apoptosis is
mediated by the depolarization of mitochondrial membranes, the depletion of glutathione,
and the generation of reactive oxygen species.79,94
Thiosemicarbazone Ligands and Metal Complexes
Thiosemicarbazones are a very unique class of compounds due to their
pharmacological applications and their versatility in coordination chemistry.95
Thiosemicarbazones and their metal complexes have long been recognized for their
potential antiviral, antibacterial, antifungal, antimalarial, and antitumor activities.96-100
Thiosemicarbazones are versatile mixed hard-soft oxygen/nitrogen-sulfur chelating
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ligands, exhibiting various binding modes with transition and some main group
metals.101,102 The presence of amide, thione and imine groups makes them potential
polydentate ligands.103
Thiosemicarbazones usually coordinate to metal centers in a bidentate mode via
the imine nitrogen and the sulfur atom of the thioamide moiety. The coordination mode
can be increased however by the incorporation of an additional donor groups as
heterocyclic substituents.95 The most common donor set involves the ONS or NNS atoms
in which one or two ligands are attached to the metal center, which is bridged through
either thiolate sulfur or a non-thiosemicarbazone coligand (i.e.N3, Cl, NCS, CH3COO,
etc.).95,104 Depending on the disposition of substituents about the imine and thioamide
groups, -pyridyl thiosemicarbzones are known to exist in three isomeric forms (Figure
18).105 Intramolecular hydrogen bonding plays a very important role in the structural
determination of the isomeric forms of thiosemicarbazones.105
As reported in literature, the anticancer activity of thiosemicarbazone metal
derivatives is much more effective than that of the free ligand.95 This is due to the change
in the binding affinity of metals to proteins and enzymes that occur following the
coordination of a thiosemicarbazone ligand to a metal center.95 This results in a change in
the interaction of the respective complex with DNA thereby causing an effect on DNA
replication and cell proliferation.95
Following the discovery of the antileukemic activity2-formylpyridine
thiosemicarbazone (Figure 19) in the 1950s, the antineoplastic activity of -Nheterocyclic thiosemicarbazones has since been thoroughly investigated.106
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Figure 18. Isomeric forms of -pyridyl thiosemicarbzones showing Z, E (anti, anti) and
E’ (syn,syn) isomeric forms.105

Figure 19. Structure of 2-formylpyridine thiosemicarbazone.105
Several reports have recently documented the preparation and biological activity of
transition metal complexes containing thiosemicarbazone ligands.105 Ribonucleotide
reductase (RR) (a mammalian enzyme) has been identified as a principal target for
thiosemicarbazones.102,107 In 1961, Peter Reichard reported the discovery of the enzyme
RR in E. coli.108,109 This enzyme was later found in all growing cells of every living
organism and in several species of viruses.108,110
Thiosemicarbazones are the strongest known inhibitor of RR both in cell-free
assay and in intact tumor cells.101 The inhibition of RR is results in the pronounced
antineoplastic efficacy of thiosemicarbazones.105,111 RR catalyzes the reductive
conversion of ribonucleotides to deoxyribonucleotides, which is a crucial, rate-limiting
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step in the pathway leading to the biosynthesis of DNA.112 The reaction involves the
replacement of the C2’-hydroxyl group on the ribose moiety by a hydrogen atom
(Scheme 4).108

Scheme 4. Ribonucleotide reduction catalysed by ribonucleotide reductase.108
RR is produced at the transition from G1 to the S phase of the cell cycle as a
prerequisite for DNA replication and is highly active in proliferating tumor cells, making
it an excellent target for tumor chemotherapy.101,113 Mammalian (class 1a) RR consists of
two non-identical subunits called R1 (

2

homodimer) and R2 (

2

homodimer).101 The R1

subunit harbors the catalytically active center consisting of redox active cysteines
regenerated by the action of thioredoxin.101 The R2 subunit contains a tyrosyl radical and
a diiron center, both of which are essential for the initiation of the reductive process at the
active site in R1.101,114
RR inhibitors are divided into four classes depending on the mode of action:
radical scavengers, chelating molecules, and nucleoside analogs.101 The inhibitory effect
of thiosemicarbazone is often attributed to their pronounced iron-chelating
properties.101,107 The chelation of iron from the R2 subunit of the enzyme, results in the
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formation of an active iron complex, which is responsible for the inhibition of the RR
enzyme.101,107
The ability of thiosemicarbazones to chelate metal ions is solely dependent on the
presence of a N,N,S tridentate “soft donor” coordination system, which allows for the
coordination of iron, copper, zinc and several other transition metals.105,111 The antitumor
activity of thiosemicarbazones is therefore assumed to originate from the capability of
these compounds to form stable metal complexes.115 According to Thelander and
Graslund,116 the existence of an active iron complex confirms the proposed mechanism,
which involves the reduction of an iron(III) complex (containing 1-formylisoquinoline
thiosemicarbazone) to form a stable iron(II) complex (in the presence of dithioreitol).116
Presently, gemcitabine and hydroxyurea (HU) (Figure 20) are the only known
clinically approved inhibitors of RR.112,117,118 Recently, Sartorelli and coworkers also
reported the synthesis and biological evaluation of 3-aminopyridine-2-carboxaldehyde
thiosemicarbazone (3-AP) and 3-aminopyridine-4-methyl-2-carboxyaldehyde
thiosemicarbazone (3-AMP) (Figure 21).119 3-AP (triapine) is the first reported
thiosemicarbazone to enter phase II clinical trials as an antineoplastic agent.102 A
comparative study of 3-AP and HU demonstrated a greater inhibitory potency for 3-AP
against L1210 leukemia cells, both in vitro and in vivo.105,120,121 3-AP was also observed
to be active against HU-resistant cells.105,120 This observation lead to the suggestion of
other possible modes of action, which may include radical reactions or inhibition of
topoisomerase II.101
The high general toxicity and the consequent low therapeutic index are the major
disadvantages associated with the use of thiosemicarbazones as antineoplastic agents.101
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Figure 20. Structure of gemcitabine and hydroxyurea. 112,117,118

Figure 21. Structure of 3-AP and 3-AMP.119
The entry of 3-AP into clinical stages, however, has led to a renewed interest in the
antineoplastic effects of thiosemicarbazone complexes.101 Recently, the biological
activity of several metal complexes containing -pyridyl and salicyladehyde (and their
analogues) thiosemicarbazones (Figure 22) have been reported in literature.101,105
Gallium(III) complexes has been reported to possess clinically useful antipoliferative
properties.122,123 The synthesis of a series of gallium(III) and iron(III) complexes with Nsubstituted -N-heterocyclic thiosemicarbazones were recently reported by Kowol et al
(Figure 23).122 The ligand binding affinity of gallium(III) is very similar to that of
iron(III), which often leads to an upset in the availability of intracellular iron.122 Gallium
interacts directly with RR and competes with iron for the binding site in the R2 unit of
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Figure 22. Structure of the -Pyridyl Thiosemicarbazone, Salicylaldehde
Thiosemicrbazone, and Benzaldehyde/Benzophenone Thiosemicarbazone Metal
Complexes.105
the enzyme.122,124,125
Pronounced differences in the cytotoxic effect were observed upon variation in
the central metal ion.101 Gallium(III) was shown to enhance cytotoxicity due to the
synergistic action of the two components.101 The complexation to iron(III), however,

Figure 23. Structure of thiosemicarbazones and their gallium(III) and iron(III)
complexes.122
resulted in a marked attenuation of the antiproliferative activity.101 The design of metal
complexes in which both the metal and the ligand is directed at the same molecular target
produces highly potent RR inhibitors due to the synergistic action of the two
components.122
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The antimicrobial and DNA cleavage activity of a series of Co(II), Ni(II), and
Cu(II) complexes with Schiff bases derived from m-chloro/nitro substituted
thiosemicarbazides and 2-methoxy benzaldehyde (possessing sulfur and azomethine
nitrogen donors) (Figure 24) were reported by Patil et al.126 Although a significant

Figure 24. Structure of Co(II), Ni(II), and Cu(II) complexes containing
thiosemicarbazone ligands.126
increase in activity was observed upon coordination, both the Schiff base ligands and
their metal complexes were shown to be highly active against some of the antifungal and
antibacterial species.126
Ruthenium complexes are believed to have low toxicity and good selectivity for
tumors.127,128 As such, ruthenium complexes are widely studied as metallodrugs.127,128
Ruthenium has been reported to possess several favorable anticancer properties and
several of these ruthenium containing complexes are known to interaction with DNA and
RNA causing a reduction in tumor growth.129-131 Imidazolium trans-[tetrachlorido(1Himidazole)-(S-dimethyl sulfoxide)ruthenate(III)] (NAMI-A) and indazolium trans[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) (Figure 25) are two of the most
promising ruthenium based complexes for clinical use as anticancer agents.132 Both
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NAMI-A and KP1019 have successfully completed phase 1 clinical trials and are
currently undergoing phase II studies.132 NAMI-A is known to exert an inhibitory effect

Figure 25. Structure of NAMI-A and KP1019.132
on metastases formation and causes a reduction in the weight of metastasis without
affecting the primary tumor.133 The application of KP1019, however, is mainly aimed at
the treatment of solid tumors such as colorectal carcinoma.133
Several researchers have demonstrated interest in the possibility of identifying a
new anticancer drug among ruthenium complexes containing thiosemicarbazone
ligands.134,135 Recently, the cytotoxicity of a series of mixed-ligand diimine ruthenium
complexes of the type [(bipy)2Ru(TSC)](PF6)2 and [(phen)2Ru(TSC)](PF6)2 (Figure 26)
was reported by Beckford et al.128 All complexes were observed to interact with DNA via
weak to moderate intercalation, and they all showed good cytotoxicity against a variety of
human cancer cell lines including MCF-7 and MDA-MB-231 (breast adenocarcinoma)
and HCT 116 and HT-29 (colorectal carcinoma) cell lines.128
In 2006, the synthesis, characterization and antiamoebic properties of several
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Figure 26. Ruthenium(II) complexes containing thiosemicarbazone ligands.128
neutral dioxovanadium(V) complexes [VO2(HL)] (H2L = I: 24, H2L = II: 25 and H2L =
III: 26; H2L are the thiosemicarbazones H2pydx-tsc (I), H2pydx-chtsc (II) and H2pydxclbtsc (III); pydx = pyridoxal, tsc = thiosemicarbazide, chtsc = N4cyclohexylthiosemicarbazide, clbtsc = N4-(2-chloro)benzylthiosemicarbazide) (Figure
27) were reported by Maurya et al.136 Upon heating, methanolic solutions of these
complexes readily dimerized to form the respective -oxo binuclear complexes
[(VOL)2

-O] (H2L = I: 27, H2L = II: 28, H2L = III: 29) as shown in Figure 27.136

Figure 27. Structure of neutral dioxovanadium(V) complexes containing
thiosemicarbazone ligands.136
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Research Aim
The main aim of this project is to synthesize, characterize and investigate the antiproliferative properties of a series of novel V(IV) compounds containing
thiosemicarbzone ligands. In this study, three thiosemicarbazone ligands will be
synthesized. The three thiosemicarbazone ligands will then be coordinated to [VO(Sal-Ltryp)(H2O)] (1), to produce three novel V(IV)-containing complexes. All ligands and
complexes will be characterized using electrochemical and several spectroscopic
techniques.
Preliminary in vitro studies will also be carried out in order to investigate the antiproliferative activity of the novel compounds. In vitro studies will be carried out using
colon cancer cell lines, and the results obtained will be compared with that of normal
non-cancerous colonic myofibroblasts. These compounds are proposed to have the
potential to be used as anticancer agents. Stability studies in DMSO solvent to ascertain
the oxidation numbers of the vanadium-containing species. Spectroscopic techniques will
be used in order to determine the identity of the products formed upon aerial oxidation in
DMSO. The hypotheses are as follows:
Vanadium(IV) complexes are resistant to aerial oxidation.
Vanadium(IV) complexes do exhibit anti-proliferative properties against
colon cancer cell lines.
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CHAPTER II
EXPERIMENTAL
Materials
Analytical or reagent grade chemicals were used throughout this study. All
reagents and solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) or
other commercial vendors, and used as received.
Instrumentation and Techniques
Microanalyses (C, H, N) were performed by Desert Analytics, Tucson, U.S.A.
and Columbia Analytical Services, 3860 S. Palo Verde Road Suite 303, Tucson, AZ
85714, U.S.A. All FT IR spectra were acquired on a Nicolet 6700 FT IR
spectrophotometer in the range 4000-400 cm-1 using the ATR accessory (with a
diamond crystal). 1H- and 13C-NMR spectra were acquired in DMSO-d6 on a Bruker
400 MHz spectrometer operating at ambient temperature. The residual 1H- and 13Cpresent in DMSO-d6 (2.49 and 39.7 ppm, respectively) were used as internal
references. Electronic absorption spectra were recorded on a HP8452 diode array
spectrophotometer using quartz cuvettes and DMSO as the solvent. Fluorescence
spectra were acquired on a Cary Eclipse fluorescence spectrophotometer (Varian Inc.)
using a slit width of 10 nm.
Electrospray Ionization Mass Spectrometry (ESI MS)
ESI MS data was collected on an HP Agilent 1956b single-quadrupole mass
spectrometer. Samples were dissolved in an acetic acid/methanol mixture and
introduced by direct injection using a syringe pump at a flow rate of 100 L s-1 while
sweeping the cone voltage from 0 to 200 V at a rate of 10 V min -1. All m/z ratios and
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percentages presented as ESI MS data were determined using the MestReNova
software.
Electrochemical Studies
Cyclic voltammetric (CV) and square wave (SQW) data were collected on a
Bioanalytical Systems Inc. Episilon workstation on a C3 cell stand at 296 K.
Measurements were carried out using a three-electrode system consisting of a 1.6 mm
platinum working electrode, a platinum wire auxiliary electrode, and a Ag/Ag+ (0.01
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. The working
electrode was polished before each experiment with alumina slurry. DMSO solutions
(1.0 mM) containing 0.10 M tetra-n-butylammonium hexafluorophosphate (TBAP) as
supporting electrolyte were saturated with argon for 15 minutes prior to each run. A
blanket of argon gas was maintained throughout the measurements and ferrocene was
used as an internal standard (E1/2 = 0.09 V versus Ag/Ag +).
X-ray Crystallography
X-ray crystallographic data collection, structure analysis and refinement, and
intensity data of the acetylethTSC were obtained by Dr. Don VanDerveer and Dr.
Frank R. Fronczek of Clemson University and Louisiana State University,
respectively. Crystallographic data were collected at 90 K on a Bruker Kappa Apex-II
CCD diffractometer equipped with CuK radiation and an Oxford Cryosystems
Cryostream cooler. The structure of acetylethTSC was solved using SHELXS137 and
refined using the SHELX97 138,139 software packages. All H atoms were visible in
difference maps. Coordinates of the NH hydrogen atoms were refined individually
while those on C were placed in idealized positions with torsional parameters refined
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for the methyl groups. Crystal data: C8H12N4S2, FW = 228.34, monoclinic, space
group = C2/c, a =10.4549(10), b = 10.8970(10), c = 18.7694(15) Å, β = 91.544(5)º, V
= 2137.6(3) Å3, Z = 8, T = 90.0(5)K, μ = 4.25 mm-1, dcalc = 1.419 g cm−3, colourless
parallelepiped, dimensions = 0.18 x 0.17 x 0.09 mm, reflections collected = 8017,
unique reflections = 1901, observed reflections (I > 2σ(I)) = 1738, Rint = 0.026, No. of
parameters = 136, R1 = 0.028, R2 = 0.069, GOF(F2) = 1.065, CCDC No. = 812348.
Cell Culture
All in vitro studies were done by Dr. Antonio González-Sarrías of the
University of Rhode Island. All cell lines were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, U.S.A.) and maintained at the University
of Rhode Island, U.S.A. Cell lines used included three human colon cancer cells:
HCT116 (human colon carcinoma), HT-29 (human colon adenocarcinoma) and Caco2 (human epithelial colorectal adenocarcinoma). Non-cancerous human colon cells,
CCD-18Co (human colon fibroblasts) were also used in this study. Caco-2 cells were
grown in EMEM medium supplemented with 10% v/v fetal bovine serum, 1% v/v Lglutamine, 1% v/v nonessential amino acids, and 1% v/v antibiotic solution (SigmaAldrich). HT-29 and HCT-116 cells were grown in McCoy’s 5a medium
supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential amino acids,
2% v/v HEPES and 1% v/v antibiotic solution. CCD-18Co cells were grown in
EMEM medium supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential
amino acids, 1% v/v L-glutamine, and 1% v/v antibiotic solution and were used from
PDL = 26 to PDL = 35 for all experiments. Cells were maintained in an incubator at
37 ºC under an atmosphere of 5% CO2/95% air atmosphere at constant humidity and
maintained in the linear phase of growth. The pH of the culture medium inside the
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incubator was determined using pH indicator paper (pHydrionTM Brilliant, pH 5.5 9.0, Micro Essential Laboratory, NY, U.S.A.). Prior to addition to the culture mixture,
all test samples were dissolved in DMSO (<0.5 % in the culture medium) by
sonication and then filter sterilised (0.2 μm). Control cells were also carried out in
parallel sequences and subjected to the same changes in medium with a 0.5 % DMSO.
Cytotoxicity Assay
This assay was carried out as described by Cory et at.140 in order to measure
the IC50 values for samples. The in vitro cytotoxicity of samples were briefly assessed
in tumour cells by a tetrazolium-based colorimetric assay taking advantage of the
metabolic conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt] to a reduced form
that absorbs light at 490 nm. Cells were counted using a hemacytometer and were
plated at 2000-5,000 cells per well, depending on the cell line, in a 96-well format for
24 hours prior to drug addition. All test samples and a positive control, etoposide 4
mg ml-1 (Sigma-Aldrich), were dissolved in DMSO (by sonication) and diluted with
media to the desired treatment concentration and the final DMSO concentration per
well did not exceed 0.5%. Control wells were also included on all plates. Following a
24, 48, or 72 hour drug-incubation period of the serially diluted test compounds at 37
C, MTS, in combination with the electron coupling agent, phenazine methosulphate,
was added to the wells and cells were incubated at 37 ˚C in a humidified incubator for
three hours. Absorbances at 490 nm (OD490) were acquired on a spectrophotometer
(SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6 software,
Sunnyvale, CA, U.S.A.) to obtain the number of surviving cells relative to control
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populations. The results are expressed as the median cytotoxic concentrations (IC 50
values) and were calculated from six-point dose response curves using 4-fold serial
dilutions. Each point on the curve was tested in. Data are expressed as mean

SE for

three replications on each cell line.
Synthesis of Ligands
9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) was prepared by
Dr. Floyd Beckford of Lyon College.128
N-Ethhymethohcarbthio. This ligand was initially synthesized by Dr. Floyd
Beckford and Dr. Ramaiyer Venkatraman. This synthesis reproduced during the
course of this research project. 4-ethyl-3-thiosemicarbazide (2.35 g, 19.7 mmol) and
o-Vanillin (3.00 g, 19.7 mmol) were placed in a 250 mL round bottom flask followed
by absolute ethanol (100 mL). Approximately 10 drops of glacial acetic acid were
added to the off-white suspension, and the reaction mixture was heated to reflux
solvent for three hours. The reaction mixture was then cooled to room temperature
and filtered through a sinistered glass crucible. The white solid obtained was washed
with ethanol (3 x15 mL) followed by ether (3 x10 mL) and allowed to air dry. Yiel d =
4.97 g (99%). The purity was checked by elemental analysis. Calc. for C 10H13N3O2S:
C, 52.15; H, 5.97; N, 16.59. Found: C, 52.53; H, 6.16; N, 17.02; Infrared spectrum
( /cm-1): FT IR ( /cm-1): 3304 (m) (-N1H), 3300 (m) (-N2H), 3130 (br) (OH), 1155
(m) (N-N), 1606 (m) (TSC (C=N)), (1267) (m) and (831) (m) (C=S).

H

(400 MHz;

DMSO-d6); 1.15 (t) (3H) (-CH3), 3.46 (s) (1H) (-CH3-OAr), 3.60 (q) (2H) (CH 2), 7.57
(s) (1H) (azomethine -CH=N), 6.78 (t) (CHar), 6.94 (dd) (CHar), 8.43 (s) (3H) (aminic
NH), 9.19 (s) (1H) (ArOH), 11.42 (s) (1H) (hydrazinic-NH); 13C (400 MHz; DMSO-
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d6);

172.90 (C=S), 165.73 (CH=N), 163.26 (-COCH3ar), 136.21 (ROH), 120.61

(CCH=Nar), 118.31 (CHar), 118.04 (CHar), 111.57 (CHar), 56.02 (OCH3), 29.95 (CH2),
15.06 (CH3).
AcetylethTSC. AcetylethTSC was synthesized and characterized by Dr.
Ramaiyer Venkatraman from Jackson State University. This synthesis was also
repeated during the course of this research project. 2-Acetylthiazole (0.636 g, 0.518
ml 5.0 mmol) was placed in a 100 ml round bottomed flask followed by anhydrous
methanol (25 mL). 4-Ethyl-3-thiocarbazide (0.596 g, 5.0 mmol) in anhydrous
methanol (25 mL) was slowly added to the solution of 2-acetylthiazole follwed by a
few drops of concentrated hydrochloric acid. The reaction mixture was stirred and
heated to reflux solvent for two hours, then evaporated to a minimum volume to form
a yellow solid. The mixture was filtered and the residue was washed with ether and
air-dried. Yield = 0.750 g (66%). A single cystal for X-ray crystallography was grown
by slow evaporation from methanol. FT IR ( /cm-1): 3164 (m) (-N1H), 3054 (m) (N2H), 1059 (m) (N-N), 1543 (m) (TSC (C=N)), (1296) (m) and (813) (m) (C=S).

H

(400 MHz; DMSO-d6); 1.16 (t) (3H) (-CH3), 2.42 (s) (3H) (CH3CH=N), 3.61 (d) (2H)
(CH2), 7.39 (d) (CHar), 7.89 (d) (CHar), 8.34 (s) (3H) (aminic NH), 10.61 (s) (1H)
(hydrazinic-NH).
Reduced Schiff base (2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic
acid). The reduced Schiff base was prepared using a known procedure involving
salicylaldehyde, amino acids, and NaBH 4, but with L-trptophan using the following
synthetic procedure:141 L-tryptophan (2.042 g, 10.0 mmol) and potassium hydroxide
(0.56 g, 10.0 mmol) were added to a 125 mL Erlenmeyer flask, followed by deionised

38
water (10 mL). Salicylaldehyde (1.029 mL, 10.0 mmol) in absolute ethanol (10 mL)
was slowly added to the mixture. The yellow solution was then stirred for thirty
minutes prior to cooling in an ice bath. The intermediate Schiff base formed in situ
was then reduced with an excess of sodium borohydride (0.46 g, 12 mmol) in water
(5 mL) containing 10 drops of 2 M sodium hydroxide. The solution was stirred for ten
minutes, and the yellow color slowly discharged. The solution was then acified with
concentrated HCl to pH 4.68 and the resulting solid was filtered off, washed with
ethanol (2 x 30 mL) and diethyl ether (2 x 30 mL), and dried. The white solid
obtained was recrystalized twice from water/ethanol (1:1). Yield = 1.08 g (35%). m/z
(ESI) (+ve mode) 311.08 (100.00%, [M+H] +), 242.42 (13.04%, [M-CHO3 + H]+),
620.36 (12.77%, [2M + H]+), 930.39 (5.02%, [3M+H] +), 1240.92 (3.92%, [4M + H] +).
FT IR ( /cm-1): 3392 (m) (indolic NH), 3055 (br) (OH), 1208 (m) (C-O)), 1494 (m)
(COOs) and 1592 (m) (COOas).

H

(400 MHz; DMSO-d6); 2.67 (d) (2H) (H (j)), 3.21

(d) (2H) ((H (h)), 3.05 (d) (2H) (H (g)), 5.91 (t) (1H) (H (d)), 6.15 (d) (1H) (H (b)),
6.31 (d) (1H) (H (l)), 6.62 (m) (1H) (H (n)), 6.62 (m) (1H) (H (o)), 6.62 (m) (1H) (H
(p)), 6.62 (m) (1H) (H (q)), 6.90 (d) (1H) (H (a)) and 7.18 (d) (1H) (H (c)); 13C (400
MHz; DMSO-d6); 28.57 (C (j)), 46.72 (C (g)), 63.61 (C (h)), 110.66 (C (n)), 111.57
(C (k)), 113.46 (C (d)), 118.50 (C (o)), 118.69 (C (q)), 121.37 (C (b)), 123.85 (C (p)),
123.89 (C (l)), 126.95 (C (f)), 127.78 (C (c)), 128.16 (C (a)), 128.34 (C (r)), 135.97
(C (m)), 164.55 (C (e)), 182.05 (C (i)).
K[(Sal-L-tryp)]. This complex was prepared using an analogous synthesis as
reported by Vanco et al.,142 but in our case, L-tryptophan was used instead of alanine. To a mixture of L-tryptophan (3.07 g, 15.0 mmol) and potassium hydroxide
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(0.85 g, 15.0 mmol) dissolved in water (5 mL), the solution of salicylaldehyde (1.57
mL, 15.0 mmol) in 10 mL of ethanol was added with stirring. The resulting yellow
solution was stirred at room temperature for 24 hours, and then, it was diluted by
ethanol (25 mL). Upon slow evaporation of solvent, a yellow oil was formed, which
was then tertuated with diethyl ether. Solution was then filtered and dried under
vacuum to give a yellow powder. Yield = 4.85 g (93%). m/z (ESI) (+ve mode) 344.05
(39.65%, [M + H]+), 300.03 (100.00%, [M - OH - K + H] +), 281.14 (46.08%, [M OH - O - K + H] +), 262.12 (1.51%, [M - COO - K + H]+), 242.62 (64.65%, [M - COO
- OH - K + H]+) and 205.20 (50.43%, [M - C7H6O - K + H] +). FT IR ( /cm-1): 3407
(m) (indolic NH), 3169 (br) (OH), 1194 (m) (C-O)), 1521 (m) (COOs), 1604 (m)
(COOas) and 1570 (m) (TSC (C=N)).

H

(400 MHz; DMSO-d6); 3.13 (t) (2H) (H (k)),

3.62 (d) (1H) ((H (i)), 4.07 (s) (1H) (H (g)), 6.59 (s) (1H) (H (t)), 6.72 - 7.06 (m) (1H)
(H (b)), 6.72 - 7.06 (m) (1H) (H (d)), 7.20 (s) (1H) (H (n)), 7.20 (m) (1H) (H (o)),
7.20 (m) (1H) (H (p)), 7.20 (m) (1H) (H (q)), 7.35 - 7.58 (m) (1H) (H (c)), 7.35 - 7.58
(m) (1H) (H (e)) and 11.17 (s) (1H) (H (s));

13

C (400 MHz; DMSO-d6); 30.16 (C

(k)), 64.82 (C (i)), 72.43 (C (q)), 111.39 (C (l)), 111.56 (C (p)), 115.74 (C (b)),
117.62 (C (d)), 117.99 (C (n)), 118.31 (C (t)), 118.33 (C (f)), 120.59 (C (o)), 123.38
(C (m)), 127.36 (C (c)), 131.77 (C (r)), 132.01 (C (e)), 163.27 (C (a)) and 172.88 (C
(j)).
Synthesis of Complexes
[Zn(Sal-L-tryp)(H2O)].0.25 H2O. [Zn(Sal-L-tryp)(H2O)].0.25H2O was prepared
as by Garcia-Raso et.al. with minor modifications to the general procedure.143 Ltryptophan (5 mmol, 1.024 g) and absolute ethanol (10 mL) was placed in a 250 mL

40
round bottomed flask and the mixture was heated and stirred at 60-70 ˚C. Salicylaldehyde
(5 mmol, 0.52 mL) in absolute ethanol (10 mL) was slowly added to the mixture. The
resulting yellow solution was stirred vigorously on a magnetic stirrer for 30 minutes and
an aqueous solution of zinc(II) acetate dihydrate (5 mmol, 1.098 g) in water (30 mL) was
added dropwise to the solution. The solution was simultaneous neutralized to pH 7 with
0.5 M KOH. The resulting solution was stirred for 1 h and the yellow precipitate formed
was filtered, washed with water, and dried under vacuum. The resulting solid was
crystallized from methanol and rotary evaporated to dryness. Yield: 1.2608g (64%). m/z
(ESI) (+ve mode) 395.11 (13.93%, [M + H]+) and 1152.92 (92.74%, [Zn3O2(Sal-L-tryp)3
+ H]+). FT IR ( /cm-1): 3405 (m) (indolic NH), 3256 (br) (OH), 1551 (m) (C-O)), 1473
(m) (COOs), 1597 (m) (COOas) and 1581 (m) (TSC (C=N)).

H

(400 MHz; DMSO-d6);

4.15 (d) (1H) (H (b)), 7.13 (m) (1H) ((H (c)), 7.06 (t) (1H) (H (d)), 7.34 (d) (1H) (H (e)),
7.25 (s) (1H) (H (g)), 3.90 (d) (1H) (H (i)), 3.19 (d) (2H) (H (j)), 6.62 (m) (1H) (H (n)),
6.62 (m) (1H) (H (o)), 6.62 (m) (1H) (H (p)), 10.70 (s) (1H) (H (r)) and 6.62 (m) (1H) (H
(q)); 13C (400 MHz; DMSO-d6); 30.64 (C (j)), 48.66 (C (i)), 69.07 (C (k)), 109.58 (C
(p)), 111.42 (C (d)), 118.28 (C (m)), 118.28 (C (n)), 118.44 (C (f)), 118.86 (C (o)),
120.90 (C (b)), 122.22 (C (l)), 124.44 (C (s)), 127.05 (C (c)), 132.87 (C (e)), 134.50 (C
(q)), 136.19 (C (g)), 167.14 (C (a)) and 179.60 (C (h)).
[VO(Sal-L-tryp)(H2O)] 1. This complex was prepared as by Costa Pessoa et
al.144 L-tryptophan (1.14 g, 5.60 mmol) and sodium acetate trihydrate (1.47 g, 10.8
mmol) was placed in a 250 mL round bottomed flask with deionized water (100 mL).
The mixture was stirred and heated at 50 ˚C to completely dissolve the L-tryptophan.
Salicylaldehyde (0.59 mL, 5.6 mmol) in absolute ethanol (14 mL) was slowly added

41
to the mixture. The resulting yellow solution was stirred vigorously on a magnetic
stirrer and an aqueous solution of VOSO 4.xH2O (0.78 g, 4.8 mmol) in water (2 mL)
was added dropwise to the solution. The solution was stirred for 30 minutes. A deep
dark brown precipitation developed immediately, and then, a heavy precipitation was
observed. The resulting solution was then filtered under vacuum. The grey solid
formed was washed with water (30 mL) followed by a ethanol-water mixture (50:50)
(30 mL) and dried. Yield = 1.19 g (63%). The purity was checked by elemental
analysis. Calc. for C 18H16N2O5V: C, 55.25; H, 4.12; N, 7.16. Found: C, 55.16; H,
4.31; N, 6.87 (lit. 144 Calc. for C18H16N2O5V: C, 55.25; H, 4.12; N, 7.16. Found: C,
55.2; H, 4.2; N, 7.1). FT IR ( /cm-1): 3478 (m) (indolic NH), 3014 (br) (OH), 1540
(m) (C-O), 1490 (m) (COO s), 1597 (m) (COOas), 1600 (m) ([(Sal-L-tryp)] C=N), and
997 (s) (V=O) (lit.144 3480 (m) (indolic NH), 3065 (br) (OH), 1630 (m) ([(Sal-L-tryp)]
(C=N)), 1600 (m) (C-O)) and 970 (s) (V=O)). UV-Visible spectrum (MeOH),
λmax./nm ( /M-1 cm-1): 558 (44) and 758 (27); (lit. 144 UV-Visible spectrum (DMSO),
λmax./nm ( /M-1 cm-1): 275 (15400) and 375 (4850), 520 (45) and 730 (20)).
Compounds 2-4 were initially synthesized by Mr. Anthony Magnusen. However,
during this research project, the following syntheses were reproduced to give higher
purity and improved yields. Compounds were also fully characterized for the first
time.
[VO(Sal-L-tryp)(MeATSC)].1.5C 2H5OH 2. A 250 mL round bottom flask was
thoroughly dried; then, (E)-2-(anthracen-9-ylmethylene)-Nmethylhydrazinecarbothioamide (0.15 g, 0.51 mmol) and [VO(Sal-L-tryp)(H2O)]
(0.20 g, 0.51 mmol) were placed in the 250 mL round bottom flask. Absolute ethanol
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(100 mL) was added to the flask and the solution was heated to reflux solvent while
stirring under argon for two hours in an oil bath at 110 ˚C. An orange-blue solution,
which was produced, was then rotary evaporated to dryness. Diethyl ether was added
to the product and the mixture was filtered under vacuum and dried. A green solid
was collected. Yield = 0.23 g (68%). The purity was checked by elemental analysis.
Calc. for C38H38N5O5.5 SV: C, 62.03; H, 5.21; N, 9.52. Found: C, 62.62; H, 5.25; N,
9.33. m/z (ESI) 666.17 (100.00%, [M + H] +), 577.08 (33.10%, [[M - C2H5N2S] + H] +,
405.14 (31.86%, [[M - C17H17N3] + H] +), 292.14 (54.60%, [MeATSC + H]+). FT IR
( /cm-1): 3308 (m) ( indolic NH), 3340 (m) (-N1H), 2976 (m) (-N2H), 1148 (m) (NN), 1544 (m) (C-O)), 1491 (m) (COO s), 1600 (s) (COOas), 1624 (m) (TSC (C=N)),
1590 (m) ([(Sal-L-tryp)] (C=N)), (1225) (m), (829) (m) (C=S), (455) (m) (V-S), and
980 (s) (V=O). UV-Visible spectrum (DMSO), λmax./nm ( /M-1cm-1): 226 (74835),
292 (sh) (17954), 316 (sh) (10046), 388 (15013), 550 (54), 592 (sh) (45), 756 (28).
[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H 2O 3. A 250 mL round bottom
flask was thoroughly dried; then, (E)-2-(4-hydroxy-3-methoxybenzylidene)-N
methylhydrazinecarbothioamide (0.065 g, 0.26 mmol) and [VO(Sal-L-tryp)(H2O)]
(0.10 g, 0.26 mmol) were placed in the 250 mL round bottom flask. Absolute ethanol
(40 mL) was added to the flask and the solution was refluxed with stirring under
argon for two hours in an oil bath at 110 ˚C to form a blue-green solution. The bluegreen solution was rotary evaporated to dryness; then, diethyl ether was added to the
product and the mixture was filtered under vacuum and dried. Yield = 0.12 g
(78%).The purity was checked by elemental analysis. Calc. for C29H30N4O7 SV: C,
53.33; H, 4.64; N, 11.11. Found: C, 53.18; H, 5.21; N, 11.09. m/z (ESI) 624.87
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(100.00%, [M - H]-), 431.90 (64.75%, [M - C11H10N2O - H]-), 407.85 (20.99%, [M C11H15N3O2S - H]-), 287.88 (12.70%, [[C 11H15N3O2S – C8H7N] - H]-), 252.00
(25.74%, [N-Ethhymethohcarbthio - H]-). FT IR ( /cm-1): 3210 (m) ( indolic NH),
3306 (m) (-N1H), 2970 (m) (-N2H), 3010 (br) (OH), 1154 (m) (N-N), 1540 (m) (CO)), 1480 (m) (COOs), 1600 (s) (COOas), 1620 (m) (TSC (C=N)), 1580 (m) ([(Sal-Ltryp)] (C=N)), (1270) (m), (802) (m) (C=S), (454) (m) (V-S) and 976 (s) (V=O).
Visible spectrum (DMSO), λmax./nm ( /M-1cm-1): 270 (sh) (10984), 288 (sh) (13874),
330 (24837), 390 (sh) (18250), 620 (852).
[VO(Sal-L-tryp)(acetylethTSC)].0.75C 2H5OH 4. A 250 mL round bottom flask
was thoroughly dried; then, 2-acetylthiozole-4,4'-dimethylthiosemicarbazone (0.12 g,
0.51 mmol) and [VO(Sal-L-tryp)(H2O)] (0.20 g, 0.51 mmol) were placed in the 250
mL round bottom flask. Absolute ethanol (40 mL) was added to the flask and the
solution was refluxed with stirring under argon for two hours in an oil bath at 110 ˚C.
An orange-blue solution which was produced was then rotary evaporated to dryness.
Diethyl ether was added to the product and the mixture was filtered under vacuum and
dried. Yield = 0.18 g (57%).The purity was checked by elemental analysis. Calc. for
C27.5H30.5N6O4.75 S2V: C, 51.92; H, 4.83; N, 13.21. Found: C, 52.49; H, 4.72; N,
10.91. m/z (ESI) 600.25 (2.71%, [M+H] +), 513.57 (100.00%, [M - C3H7NS + H] +),
482.38 (37.11%, [M - C7H5NO] + H] +), 336.06 (4.13%, [[M - C17H15N2O] + H]+,
636. 82 (2.75%, [M + 0.75 C2H5OH + H] +). FT IR ( /cm-1): 3229 (m) ( indolic NH),
3310 (m) (-N1H), 2976 (m) (-N2H), 1149 (m) (N-N), 1545 (m) (C-O)), 1480 (m)
(COOs), 1600 (s) (COOas), 1624 (m) (TSC (C=N)), 1580 (m) ([(Sal-L-tryp)] (C=N)),
(1287) (m), (819) (m) (C=S), (455) (m) (V-S) and 982 (V=O). Visible spectrum
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(DMSO), λmax./nm ( /M-1cm-1): 276 (21969), 352 (14227), 558 (80), 590 (sh) (70),
756 (38).
Oxidized [VO(Sal-L-tryp)(H2O)] (compound 1) in DMSO. [VO(Sal-Ltryp)(H2O)] 1 (0.1 g, 0.26 mmol) and dimethylsulfoxide (10 mL) was placed in an
evaporating dish and the resulting solution was left to evaporate for 32 days. Yield =
0.09 g. m/z (ESI) (+ve mode) 468.60 (1.67, [M + H] +), 242.41 (100.00, [M - OH DMSO - C8H7N + H] +), 451.05 (48.25, [M - OH + H]+), 763.68 (30.06, [[V2O3(Sal-Ltryp)2] + H]+), 776.77 (49.36, [[V2O3(Sal-L-tryp)2(H2O)] + H]+) and 918.28 (3.13,
[[V2O3(Sal-L-tryp)2(DMSO)2] + H] +). FT IR ( /cm-1): 3185 (m) ( indolic NH), 3194
(br)(OH), 1551 (m) (C-O)), 1497 (m) (COOs), 1618 (s) (COOas), 1667 (m) (TSC
(C=N)), 1581 (m) ([(Sal-L-tryp)] (C=N)), 1164 (m), 1213 (m) (S=O), 949 (s) (V=O).
H

(400 MHz; DMSO-d6); 2.52 (d) (3H) (H (a)), 2.52 (d) (3H) ((H (b)), 10.89 (s) (1H)

(H (c)), 7.06 (S) (1H) (H (d)), 7.22 (m) (1H) (H (e)), 7.22 (m) (1H) (H (f)), 7.52 (d)
(1H) (H (g)), 8.06 (d) (2H) (H (h)), 3.36 (s) (1H) (H (i)), 3.00 (s) (2H) (H (j)), 7.22
(m) (1H) (H (k)), 7.22 (m) (1H) (H (l)), 7.22 (m) (1H) (H (m)), 7.22 (m) (1H) (H (n)),
9.93 (s) (1H) (H (o)) and 7.06 (s) (1H) (H (p)).
Oxidized [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (compound 3) in
DMSO. [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H 2O 3 (0.1 g, 0.16 mmol) and
dimethylsulfoxide (10 mL) was placed in an evaporating dish and the resulting
solution was left to evaporate for 32 days. Yield = 0.09 g. m/z (ESI) (+ve mode)
470.01 (0.50, [M + H]+), 252.26 (100.00, [N-Ethhymethohcarbthio + H] +), 451.96
(2.97, [M - OH + H]+), 702.75 (2.15, [M - OH + N-Ethhymethohcarbthio + H] +),
763.22 (0.74, [[V2O3(Sal-L-tryp)2 + H]+), 775.40 (1.08, [[V2O3(Sal-L-tryp)2( H2O)] +
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H]+) and 916.44 (0.75, [[V2O3(Sal-L-tryp)2( DMSO)2] + H] +). FT IR ( /cm-1): 3193
(br)(OH), 1666 (m) (C=N), 1600 (C=O), 1550 (m) (C-O)), 1133 (m), 1157 (m) (S O),
946 (s) (V=O).

H

(400 MHz; DMSO-d6); 2.52 (d) (3H) (H (a)), 2.52 (d) (3H) ((H

(b)), 10.43 (s) (1H) (H (c)), 6.96 (s) (1H) (H (d)), 7.22 (m) (1H) (H (e)), 7.22 (m)
(1H) (H (f)), 7.42 (d) (1H) (H (g)), 8.00 (d) (2H) (H (h)), 3.34 (s) (1H) (H (i)), 3.00
(s) (2H) (H (j)), 7.22 (m) (1H) (H (k)), 7.22 (m) (1H) (H (l)), 7.22 (m) (1H) (H (m)),
7.22 (m) (1H) (H (n)), 9.95 (s) (1H) (H (o)) and 6.96 (s) (1H) (H (p)).
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CHAPTER III
RESULTS AND DISCUSSIONS
Synthesis and Characterization of the Ligands
Two novel thiosemicarbazones (E)-N-ethyl-2-(4-hydroxy-3
methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-Nethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC) were
synthesized as shown in Scheme 5.

Scheme 5. Synthesis of the thiosemicarbazones.
9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) was synthesized as by
Beckford et al.128 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the
reduced Schiff base) was also prepared using a known procedure 141 involving
salicylaldehyde, amino acids, and NaBH 4, but with L-tryptophan (Scheme 6).
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Scheme 6. Synthesis of 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid.
Elemental and Mass Spectroscopic Analyses
Elemental analyses were carried out on N-Ethhymethohcarbthio, and the
percentage values found for C, H, and N as an assessment of the purity are discussed in
this chapter. ESI MS spectroscopic data were acquired for the reduced Schiff base and
K[(Sal-L-tryp)] (See Appendix, Figures A1 and A2) and the data is presented in Table 2.
The ESI MS data for the reduced Schiff base and K[(Sal-L-tryp)] were acquired in
the positive ion mode of the mass spectrometer. The ESI MS spectrum acquired for the
reduced Schiff base (using NH4OH/NH4CH3CO2 at pH 9.65 as solvent) revealed a base
peak at m/z = 311.08, corresponding to [M + H]+ ion. Four peaks assigned to the
fragments [M - CHO3 + H]+, [2M + H]+, [3M + H]+ and [4M + H]+ were also observed at
m/z = 242.42, m/z = 620.36, m/z = 930.39, and m/z = 1240.97, respectively. The ESI MS
spectrum of K[(Sal-L-tryp)], acquired in methanol, revealed a base peak at m/z = 300.03,
which is attributed to the [M - HO - K + H]+ ion. The peak at m/z = 344.05 was assigned
to the [M + H]+ ion while the fragments at m/z = 205.20, m/z = 242.62, m/z = 262.12 and
m/z = 281.14 were assigned to [M - C7H6O - K + H]+, [M - COO - OH - K + H]+, [M COO - K + H]+ and [M - OH - O - K + H]+, respectively.
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Table 2
Mass spectroscopic data of the Reduced Schiff base (2-(2-hydroxybenzylamino)-3-(1Hindol-3-yl)propanoic acid) and K[(Sal-L-tryp)].

Species

Exact
Mass/gmol-1

Species

m/z

Relative
Intensity

Reduced Schiff
Base #

310.13

[M+ H]+
[M - CHO3 + H]+
[2M + H]+
[3M + H]+
[4M + H]+

311.08
242.42
620.36
930.39
1240.92

100.00
13.04
12.77
5.02
3.92

K[(Sal-L-tryp)] #

346.07

[M + H]+
[M - OH - K + H]+
[M - OH - O - K + H]+
[M - COO - K + H]+
[M - COO - OH - K + H]+
[M - C7H6O - K + H]+

344.05
300.03
205.20
242.62
262.12
281.14

39.65
100.00
50.43
64.65
1.51
46.08

# - positive mode

X-ray Crystallographic Studies on AcetylethTSC
A single crystal of acetylethTSC was grown by slow evaporation of a solution
containing methanol as solvent. The molecular structure with the atomic numbering
scheme of acetylethTSC is shown in Figure 28 while Table 3 shows the crystal data and
structure refinement (see Appendix, Figures AJJ-AMM for selected bond lengths and
angles).
The molecule was observed to be nearly planar with its 14 non-hydrogen atoms
having a mean deviation of 0.029 Å from their mean plane. The largest deviation is
0.0719(4) Å for S2 as a result of a very slight tilt of the thiazole ring from the rest of the
molecule as given by the S2-C3-C2-N1 torsion angle, 3.3(2)º. The near-planarity of the
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molecule is likely due to the N3-H...N1 intramolecular interaction with N...N distance
2.588(2) Å, H...N distance 2.20(2) Å, and a rather small N-H...N angle for a hydrogen

Figure 28. An ORTEP diagram of acetylethTSC (identification code = Venkat35).
Table 3
Crystal data and structure refinement for acetylethTSC (identification code = Venkat35).

Identification code

Venkat35

Empirical formula

C8H12N4S2

Formula weight

228.34

Temperature

90.0(5) K

Wavelength

1.54178 Å

Crystal system, space group

Monoclinic, C2/c

Unit cell dimensions

a = 10.4549(10) Å, = 90º
b = 10.8970(10) Å, = 91.544(5)º
c = 18.7694(15) Å, = 90º
Volume 2137.6(3) Å3

Z, Calculated density

8, 1.419 Mg/m3

Absorption coefficient

4.251 mm-1

F(000)

960

Crystal size

0.18 x 0.17 x 0.09 mm

Theta range for data collection

5.8 to 68.1º
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Table 3 (continued).

Identification code

Venkat35

Limiting indices

-12<=h<=12, -12<=k<=13, -22<=l<=22

Reflections collected / unique

8017 / 1901 [Rint = 0.026]

Completeness to theta = 66.6º

99.1%

Absorption correction

Semi-empirical from equivalents

Max. and min. transmission

0.701 and 0.515

Refinement method

Full-matrix least-squares on F2

Data / restraints / parameters

1901 / 0 / 136

Goodness-of-fit on F2

1.065

Final R indices [I>2 (I)]

R1 = 0.0276, wR2 = 0.0691

R indices (all data)

R1 = 0.0312, wR2 = 0.0715

Extinction coefficient

0.00011(3)

Largest diff. peak and hole

0.257 and -0.262 e Å -3

bond, 110(2)º. The N1=C2 formal double bond has distance 1.284(2) Å, the N1-N2
distance is 1.3691(18) Å, and the thione distance C1=S1 is 1.6814(16) Å. It is known that
the thiosemicarbazone group can present a thione-thiol tautomerism.128 The C(1)-S(1)
distance (1.6814 Å) is similar to that found in a methyl analogue of 2-acetyl-2-thiazoline
thiosemicarbazone which is in the thione form as a solid,145 which indicates that
acetylethTSC is in that form. The N2-H group donates an intermolecular hydrogen bond
to thione S1, forming centrosymmetric hydrogen-bonded dimers with N...S distance
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3.4651(15) Å. Thiazole N atom N4 is not involved in hydrogen bonding as shown in
Figure 29.

Figure 29. Hydrogen bonding in acetylethTSC (identification code = Venkat35).
FT IR Spectroscopy
Thiosemicarbazones are known to exhibit characteristic bands in specific
energy regions corresponding to various functional groups. 128,146 FT IR spectra were
acquired for each ligand (see Appendix, Figures A3-A7) and significant FT IR
spectral bands of the free ligands are shown in Table 4. FT IR spectral data obtained
for the reduced Schiff base and K[(Sal-L-tryp)] are also presented and used to confirm
the existence of various spectral bands observed in the FT IR spectra of the free
ligands.
The stretching frequencies of the

N-H),

(C N), and (C S) functional

groups are very useful when determining the mode of coordination of the
thiosemicarbazone ligands.147 The corresponding spectral bands occur in the regions
3100 - 3500 cm-1, 1580 - 1630 cm-1, 1000 - 1200 cm-1 and 820 - 900 cm-1,
respectively. 147 Thiosemicarbazones have been shown to exhibit thione-thiol
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Table 4
FT IR data for the ligands.

–N1H2
(NH)
/cm-1

N2H
(NH)
/cm-1

(N-N)
/cm-1

(C-O)
/cm-1

3201 (w)

1075
(m)

-

3304 (m)

3300 (w)

1155 (m)

-

-

3164 (m)

3054 (w)

1059 (m)

K[(Sal-L-tryp)]

3407 (m)

-

-

Reduced Schiff base
ligand

3392 (m)

-

-

Compound

Indolic
(NH)
/cm-1

MeATSC

-

N-Ethhymethohcarbthio

-

AcetylethTSC

3399 (m)

s (COO)
-1

/cm

as (COO)
-1

/cm

TSC
(C=N)
/cm-1

Sal-Ltryp
(C=N)
/cm-1

(C=S)
/cm-1

(V-S)
/cm-1

(OH)
/cm-1

-

1621 (m)

-

1255 (m), 841
(m)

-

-

-

-

1606 (m)

-

1267 (m), 831
(m)

-

3130 (br)

-

-

-

1543 (m)

-

1296 (m), 813
(m)

-

-

-

1194 (m)

1521 (m)

1604 (m)

-

1570
(m)

-

-

3169 (br)

-

1208 (m)

1494 (m)

1592 (m)

-

-

-

-

3055 (br)

-
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tautomerism due to the presence of a thioamide -NH-C=S functionality (Figure 30).148
Recently, it was reported that thiosemicarbazones can coordinate to metal centers

Figure 30. Tautomerism in thiosemicarbazones.128
either as a neutral (thione) or as a mono-anionic (thiolate) ligand. 128 The question of
thione-thiol tautometism in the ligands were ruled out due to the absence of a
characteristic

((S-H) spectral band (in the region 2600 to 2500 cm -1) in the

respective FT IR spectra. 147,149-151 The FT IR spectra of the ligands in our case also
exhibited two stretching frequencies in the (N-H) region, confirming that the ligands
are coordinated as the thione form.128,148,152-154
When evaluating the nature of the bonding in thiosemicarbazone complexes,
the (N-H) stretching frequency is known to play a very important role. 155 The bands
assigned to (N-H) can be split into two regions: (i) 3450 to 3210 cm -1 due to the N1H2 group, (ii) 3180 to 3150 cm -1 due to the -N2H group.146 The (N-H) stretching
frequency of the -N1H2 group was observed at 3399 cm -1, 3304 cm -1, and 3164 cm -1
for MeATSC, N-Ethhymethohcarbthio, and acetylethTSC, respectively. The (N-H)
stretching frequency of the -N2H group was observed 3201 cm -1, 3300 cm-1, 3054 cm1

and 2831 cm-1 for MeATSC, N-Ethhymethohcarbthio, acetylethTSC, and the

reduced Schiff base, respectively.
Stretching frequencies observed in the regions 1620 to 1605 cm -1 are
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commonly assigned to the (C=N) moiety of the thiosemicarbazone
ligands.148,152,153,156 Spectral bands corresponding to (C=N) moiety were observed at
1621 cm-1, 1606 cm -1, and 1543 cm -1 for MeATSC, N-Ethhymethohcarbthio, and
acetylethTSC, respectively. 128 A similar stretching frequency was also observed at
1570 cm-1 in the FT IR spectrum of K[(Sal-L-tryp)], corresponding to the azomethine
group of the Sal-L-tryp moiety.142 The absence of a similar (C=N) stretching
frequency in the FT IR spectra of the reduced Schiff base suggested that the ligand
was successfully formed and confirmed the accuracy of the assignment.
Spectra bands of medium intensity observed in the regions 841-816 cm-1 and
1255-1295 cm-1 for each thiosemicarbazone ligand was assigned to the stretching
frequency (C S) moiety.152,157,158 Stretching frequencies assigned to the (C S) moiety
were observed at 841 cm-1, 831 cm-1 and 813 cm-1, and 1255 cm-1, 1267 cm-1 and 1296
cm-1 for MeATSC, N-Ethhymethohcarbthio and the acetylethTSC, respectively.
NMR Spectral Studies
NMR spectral data were acquired for N-Ethhymethohcarbthio ligand,
acetylethTSC, the reduced Schiff base, and K[(Sal-L-tryp)]. Based on the solubility of
our ligands, N-Ethhymethohcarbthio, acetylethTSC and K[(Sal-L-tryp)] were dissolved in
DMSO-d6 whereas the reduced Schiff base was dissolved in D2O/NaOD at pH 9. Figure
31 shows the lettering system used for the assignments of protons and carbons in the
experimental section for the reduced Schiff base and K[(Sal-L-tryp)] (see Appendix,
Figures A8 to A11).
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Figure 31. Assignments used for the 1H and 13C NMR data acquired for the reduced
Schiff base and K[(Sal-L-tryp)] in DMSO-d6.
N-Ethhymethohcarbthio and AcetylethTSC
The 1H NMR spectra of N-Ethhymethohcarbthio and acetylethTSC are shown
in Figures 32 and 33. The basic component of thiosemicarbazone ligand system is
generally represented by the moiety: -C2=N3-N2H-C1.146 In order to demonstrate the
usefulness of NMR in the characterization of metal-ligand bonding, the NMR ( 1H
and13C) data of the rings at C2 carbon of N-Ethhymethohcarbthio and acetylethTSC is
briefly delineated.146
In the 1H NMR spectra of N-Ethhymethohcarbthio and acetylethTSC, a singlet
at 11.42 ppm and 10.61 ppm, similar to the previously reported data of MeATSC and
ATSC thiosemicarbazone ligands, was also present. 128,147,159 Based on spectroscopic
data available in the literature, these signals are inferred to be due to the N(2) -H
protons.152,159,160 The hydrazinic protons (N(2)-H) of “free” thiosemicarbazone
ligands are known to appear as single broad peaks in a fairly wide range ( = 8.7 -15
ppm) depending on the nature of the substituents at C2 carbon atom. 146,161-164 This
signal is therefore used as a diagnostic test for the identification of isomers. 128
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Figure 32. 1H NMR spectra of N-Ethhymethohcarbthio in DMSO-d6.
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Figure 33. 1H NMR spectra of acetylethTSC in DMSO-d6.
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According to Afrasiabi, 165 a resonance signal in the range

= 13-15 ppm,

suggests that the ligand is in the E form. A resonance signal in the range

= 9-12

ppm, however, suggests that the ligand is in the Z form. Based on this analysis, the
N-Ethhymethohcarbthio and acetylethTSC ligands both existed as the respective Z
isomers. The lack of a resonance signal at ca.

= 4.0 ppm attributable to a -SH proton

resonance confirmed that both ligands existed in the thione form when in solution
(even a solvent as polar as DMSO). 128 An X-ray crystallographic study on
acetylethTSC also confirmed the existence of the thione moiety
.

The azomethine (-C2H) protons of free thiosemicarbazone ligands have been
reported to resonate in the range

= 6.6 to 7.9 ppm.146,147 The singlet observed at

=

7.57 ppm in the NMR spectrum of the N-Ethhymethohcarbthio ligand was therefore
assigned to the azomethine moiety. Although a similar peak was absent in the 1H
NMR spectrum of acetylethTSC, a singlet observed at 2.42 ppm was assigned to the
methyl group present at C 2 atom.
The resonance signals observed at

= 8.43 ppm and 8.34 ppm were assigned

to proton of the N1H(R) group (where R = ethyl group) in N-Ethhymethohcarbthio
and acetylethTSC, respectively. 128 Quintets assigned to methylene protons were
observed at

= 3.60 ppm and

= 3.61 ppm for N-Ethhymethohcarbthio and

acetylethTSC, respectively. Adjacent methyl protons were observed as triplets at
1.15 ppm and

=

= 1.14 ppm for N-Ethhymethohcarbthio and acetylethTSC,

respectively. In the 13C NMR spectra, the corresponding resonance signals for the
methylene and the methyl carbons were also observed at
ppm, respectively.

= 38.28 ppm and

= 14.60
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In the 1H and 13C spectra of N-Ethhymethohcarbthio, a resonance signal
observed at = 3.46 ppm was assigned to the methoxy protons while the
corresponding carbon signal was observed at
observed at

= 11.41 ppm and in the region

= 58.85 ppm. The resonance signals
= 6.76-7.57 ppm were assigned to the

phenolic proton (PhOH), and the aromatic protons of the N Ethhymethohcarbthio
ligand, respectively. 147
The resonance signals assigned to the C 1 and C2 carbon atoms of free
thiosemicarbazones are known to appear in the ranges,

= 177.40 to 178.86 ppm and

= 132.56 to 163.43 ppm, respectively. 146 In the 13C NMR spectrum of NEthhymethohcarbthio, the resonance signals observed at

= 176.50 ppm and

=

177.54 ppm were therefore assigned to the C 1 and C2 carbon atoms, respectively. All
other aromatic signals were observed in the range

= 112 to

= 146 ppm.128

Electrochemical Studies
The electrochemical analysis of thiosemicarbazone ligands is very sparse in
literature. In this section we attempted to analyze the electrochemical properties of our
“free” ligands. Figures 34 and 35 (See Appendix, Figures A13 and A14 for the square
wave voltammograms for the ligands) shows the respective cyclic voltammograms for
each ligand. Table 5 shows the data obtained from electrochemical studies of all ligands.
The assignment of redox peaks were done using the cyclic voltammograms shown in
Figures 34 and 35. Square wave voltammograms within the potential window of 0 to
+1.0 V versus Ag/Ag+ (See Appendix, Figures A13 and A14) were used in order to
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Figure 34. A cyclic voltammogram of a 1.0 mM solution of K[(Sal-L-tryp)] in DMSO.
Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. Supporting electrolyte =
0.1 M TBAP. Scan rate = 100 mV s-1.
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Figure 35. Cyclic voltammograms of 1.0 mM solutions of thiosemicarbazone ligands in
DMSO. Electrodes: platinum working electrode, platinum auxiliary electrode and
Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode.
Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1.
confirm the assignments made based on cyclic voltammetry. Previously reported
electrochemical studies have shown that L-tryptophan produces an irreversible anodic
peak in the region +0.8 V to +0.9 V versus Ag/Ag+ at a scan rate of 100 mV s -1.166,167
pH studies involving the electrochemical oxidation of L-tryptophan have proven that
L-tryptophan is oxidized via a two electron/two proton process occurring at the amine
group (of the indole moiety) and the methyl group (present in the side chain). 168 A
similar irreversible anodic peak corresponding to the oxidation of L-tryptophan
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Table 5
Electrochemical data of 1.0 mM solutions of ligands.

Species

E/V

Assignment

[K(Sal-L-tryp)]

Epa = +0.75
Epa = +0.16
E1/2 = -0.21
Epc = -0.97
Epc = -1.50

L-tryp0/+
PhO-/.
PhO-/.
L-tryp+/0

MeATSC

Epa = +0.84
Epa = +0.75
Epa = +0.60
Epa = -0.17
E1/2 = -1.63
Epc = -0.14
Epc = -0.49
Epc = -0.93

R2C=S0/+.
Oxidation of anthracene moiety
[R2C=S]0/+. → [R2C-S-S-CR2]2+ + 2eformation of cation radical
HC=N/CH2-NH
reduction of cation radical
reduction of disulfide cation
C=S → C=SH

NEpa =
Ethhymethohcarbthio Epa =
Epa =
Epa =
Epa =
E1/2 =
Epc =
Epc =
Epc =

+0.80
+0.51
+0.37
-0.17
-1.11
-1.60
-0.36
-0.52
-1.08

R2C=S0/+.
[R2C=S]0/+. → [R2C-S-S-CR2]2+ + 2eOxidation of phenolate in vanillin
moiety
formation of cation radical
formation of cation radical
HC=N/CH2-NH
reduction of cation radical
reduction of disulfide cation
C=S → C=SH

AcetylethTSC

+0.85
+0.75
+0.48
-0.17
-1.04
-1.38
-1.61
-0.25
-0.53
-0.86
-1.07

R2C=S0/+.
[R2C=S]0/+. → [R2C-S-S-CR2]2+ + 2eformation of cation radical
formation of cation radical
HC=N/CH2-NH
reduction of cation radical
reduction of disulfide cation
C=S → C=SH

Epa
Epa
Epa
Epa
Epa
Epa
Epa
Epc
Epc
Epc
Epc

=
=
=
=
=
=
=
=
=
=
=

Note. Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s -1.
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was also observed at +0.75 V in the CV of K[(Sal-L-tryp)] (Figure 34). The
assignment of this peak was also confirmed by the appearance of a similar anodic
redox peak at +0.60 V in the SQW voltammogram of K[(Sal-L-tryp)] (see Appendix,
A13). The existence of an irreversible cathodic peak, corresponding to catalytic
hydrogen reduction, have also been reported during electrochemical studies of Ltryptophan.169-171 In the CV of K[(Sal-L-tryp)], the irreversible cathodic peak
observed at -1.5 V was assigned to catalytic hydrogen reduction.
Based on similar work reported by Thomas et al.,172 an irreversible anodic redox
peak at +0.16 V in the cyclic voltammogram of K[(Sal-L-tryp)] was also assumed to be
due to the phenolate moieties to form into a phenoxyl radical. This assignment was also
confirmed by the appearance of an anodic redox peak at +0.12 V in the square wave
voltammogram of K[(Sal-L-tryp)]. The redox potential of the one-electron transfer
assigned to the oxidation of the phenolate moiety was also observed to vary depending on
the electrostatic environment surrounding the redox active phenolate group.172 A
reversible redox wave at E1/2 = -0.21 V, attributed to the phenoxyl/phenolate redox couple
of the non-coordinated, electron-rich phenolate moiety, was also observed in the cyclic
voltammogram of K[(Sal-L-tryp)].172
Recently, electrochemical studies of thiosemicarbazones has shown the
existence of an irreversible cathodic redox peak in the region, -1.26 V to -1.67 V,
corresponding to the reduction of the imine moiety of the thiosemicarbazone
functional group.50,159,173 An increase in the electron withdrawing character of
substituents present in a compound is known to have a significant effect on the
stability of the respective compound.174 The presence of electron donating substituent
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increases the electron density at the reduction centers, making the respective
compound more susceptible to oxidation and therefore less stable.174 The reversible
nature of the redox peaks (attributed to the reduction of the imine moiety) observed
for our thiosemicarbazone ligands is therefore accounted for by the presence of non
electroactive electron withdrawing groups on the iminic carbon of the respective
thiosemicarbazone ligands. 174 The cyclic voltammogram of each ligand exhibited a
reversible redox waves corresponding to the reduction of the imine moiety. 50,159,173
This reversible redox wave was observed at -1.63 V, -1.60 V and -1.61 V for
MeATSC, N-Ethhymethohcarbthio, and acetylethTSC ligand, respectively.
Thiocarbonyl compounds, including thioureas, thiocaronates, and mono- and
dithiocarbamates, are known to produce stable dimeric dications containing disulphide
linkages upon chemical oxidation.175,176 An outline of the suggested oxidative electrontransfer mechanism of our thiosemicarbazone ligands is shown in Scheme 7. Recently,
the cyclic voltammograms of thioureas were shown to exhibit two irreversible anodic
redox peaks, as well as an irreversible cathodic redox peak resulting from the reduction
of an oxidation product.175,176
The cyclic voltammogram of each ligand exhibited two similar irreversible anodic
redox peaks and a corresponding irreversible anodic redox peak. These peaks were
suggested to be due to the formation of cationic species as shown in Scheme 7.
Irreversible anodic redox peaks at were observed at +0.84 V and +0.60 V for MeATSC,
+0.80 V and +0.51 V for N-Ethhymethohcarbthio and at +0.85 V and +0.48 V for
acetylethTSC. The anodic redox peaks observed at +0.60 V, +0.51 V and +0.48 V were
suggested to result from the oxidation of the respective thiosemicarbazone ligands to a
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Scheme 7. Electrochemical oxidation of the thione group of a thiosemicarbazone to form
a dimeric cation.
highly reactive radical cation followed by the formation of a dimeric species
containing a disulphide bond. 176 According to Scheme 7, dimerization occurs either
by direct coupling of two radical cations or by the addition of a radical cation to a
neutral thiosemicarbazone ligand. 176 The irreversible anodic redox peaks observed at
+0.84 V, +0.80 V and +0.85 V were therefore assigned to the one-electron oxidation
of the resultant dimeric radical cation. 176
The reduction of the thione functional group of a thiosemicarbazone moiety,
have previously been reported to produce an irreversible cathodic peak at -1.06 V.177179

Previously reported electrochemical studies on thiosemicarbazone ligands have

also shown the existence of an irreversible cathodic peak at -1.06 V.177-179 Similar
irreversible cathodic peaks (assigned to the reduction of the thione group) were also
observed at -0.93 V, -1.08 V and -1.07 V, for MeATSC, N-Ethhymethohcarbthio, and
acetylethTSC, respectively.
According to Refaey et al.,174 thiosemicarbazones are capable of participating in a
series of electrochemical oxidation reactions which eventually leads to the generation of
radical cations.174 Electrochemical oxidative reactions (Scheme 8) were also evident in
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our case as illustrated by the presence of at least one irreversible anodic redox peak in the
cyclic voltammogram of each thiosemicarbazone ligand. The irreversible anodic redox
peaks corresponding to the generation of radical cations were observed at -0.17 V for
MeATSC, at -0.17 V and at -1.11 V for N-Ethhymethohcarbthio, and at -0.17 V and -1.04
V for acetylethTSC. The previously formed radical cations later react with residual water
present in the medium to form adducts, which undergoes the abstraction of a second
proton to form thiadiazoles.174 The appearance of additional irreversible cathodic redox
peaks are reported to be attributed to subsequent reduction of the previously formed
radical cations.174 Irreversible cathodic redox peaks, observed at -0.14 V, -0.36 V and –
0.25 V, were therefore assigned to the reduction of cation radicals for MeATSC, NEthhymethohcarbthio, and acetylethTSC, respectively.
According to Li et al.,180 oxidation of vanilllin is also known to proceed through
the production of relatively stable carbocation species. The oxidation of vanillin was
shown to produce a quasi-reversible redox wave with the oxidative and reductive peak
occurring at +0.19 V and +0.14 V, respectively. We are also proposing a similar
oxidative reaction for our N-Ethhymethohcarbthio thiosemicarbazone ligand. In our case,
however, an irreversible anodic redox peak corresponding to the oxidation of the vanillin
moiety of the N-Ethhymethohcarbthio ligand was observed at +0.37 V. All other ligand
based peaks that were not mentioned in this discussion is assumed to be due to the
formation of cation radical species.
The cyclic voltammogram of anthracene is known to exhibit a reversible
redox wave in the region +0.84 V to +0.90 V.181,182 An irreversible anodic redox peak at
+0.75 V was observed in the cyclic voltammogram of MeATSC. This irreversible anodic
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Scheme 8. Proposed electrochemical oxidation of the thione group.174
redox peak was assigned to the oxidation of the anthracene moiety present in the
MeATSC ligand. This assignment was also confirmed by the appearance of an anodic
redox peak at +0.82 V in the square wave voltammogram of the MeATSC ligand.
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Synthesis and Characterization of the Complexes
Elemental and Mass Spectroscopic Analyses
Elemental analyses were carried out on compounds 1-4. Table 6 shows the
respective percentage values found for C, H, and N as an assessment of the purity for
the respective compounds. The percentage of N found in compound 4 was 10.91%
versus the calculated value of 13.21%. This discrepancy is suggested to be due to
experimental errors and loss of ethanol as solvate during the elemental analysis. ESI
MS analysis of compound 4, as discussed below proves the existence of the species,
Table 6
Elemental analysis data for compounds 1-4.

Compound

Calculated

Found

C
H
N

55.25
4.12
7.16

55.16
4.31
6.87

2

C
H
N

62.03
5.21
9.52

62.62
5.25
9.33

3

C
H
N

53..33
4.64
11.11

53.18
5.21
11.09

4

C
H
N

51.92
4.83
13.21

52.49
4.72
10.91

1

[VO(Sal-L-tryp)(acetylethTSC)] and [VO(Sal-L-tryp)(acetylethTSC)]0.75C 2H5OH.
ESI MS spectral data were acquired for compounds 2-4, [Zn(Sal-Ltryp)(H2O)].0.25H2O and the products obtained from oxidised DMSO solutions of

69
compounds 1 and 3 (see Appendix, Figures A15-A22). Table 7 shows the ESI MS
data acquired for the respective complexes while Schemes 9-11 shows the proposed
species formed during ESI MS acquisition compounds 2-4.
Compounds 2-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. The ESI MS spectra of
compounds 2-4 were acquired in methanol. Each spectra exhibited base peaks
corresponding to the respective molecular ions. These peaks were observed at m/z =
666.17, m/z = 624.87, and m/z = 513.57 for compounds 2, 3, and 4, respectively. Base
peaks obtained for compounds 2 and 4 were observed in the positive ion mode of the
mass spectrometer. The base peak for compound 3, however, was observed in the
negative ion mode of the mass spectrometer due to the deprotonation of the phenol
moiety of the N-Ethhymethohcarbthio ligand. All other fragments observed for
compound 2-4 are assigned as shown in Table 7.
The ESI MS spectrum of [Zn(Sal-L-tryp)(H2O)].0.25H2O was acquired in the
positive mode of the spectrometer and methanol was used as the solvent. The peak at
m/z = 395.11 was assigned to the [M + H] + ion. X-ray crystallographic studies of
similar [N-salicylidene-L-aminoacidato)Zn(II)] complexes have proven that these
complexes are capable of forming binary and polymeric species. 143 The base peak,
attributed to the formation of a trinuclear species, was therefore observed at m/z =
1152.92 in the ESI MS spectrum of [Zn(Sal-L-tryp)(H2O)].0.25H2O. All other peaks
(corresponding to the formation of various polymeric species) were assigned as
shown in Table 7.
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Table 7
Mass spectroscopic data of compounds.
(A)

Compounds 1-4, and [Zn(Sal-L-tryp)(H2O)].0.25H2O.
Species

[VO(Sal-L-tryp)(MeATSC)] #

[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)] †

[VO(Sal-L-tryp)(acetylethTSC)] #

Exact
Mass/gmol-1

Species

m/z

Relative
Intensity

666.14

[M + H]+
[M - C2H5N2S + H]+
[M - C17H17N3 + H]+
[MeATSC+ H]+

666.17
577.08
405.14
292.14

100.00
33.10
31.86
54.60

[M - H][M - C11H10N2O - H][M - C11H15N3O2S - H][[C11H15N3O2S – C8H7N] - H][N-Ethhymethohcarbthio- H]-

624.87
431.90
407.85
287.88
252.00

100.00
64.75
20.99
12.70
25.74

[M + H]+
[M - C3H7NS + H]+
[M - C7H5NO + H]+
[M - C17H15N2O + H]+

600.25
513.57
482.38
336.06

2.71
100.00
37.11
4.13

636. 82

2.75

395.11

13.93

626.13

601.09

[VO(Sal-L-tryp)(acetylethTSC)].0.75 C2H5OH#

635.62

[Zn(Sal-L-tryp)(H2O)].0.25 H2O #

392.54

[[VO(Sal-Ltryp)(acetylethTSC)].0.75 C2H5OH
+ H]+
[M+ H]+

# - positive mode
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† -negative mode
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Table 7 (continued).
(B)

Oxidized products isolated from compounds 1 and 3.

Species

Exact
Mass/gmol-1

Species

m/z

Relative
Intensity

[VO(Sal-L-tryp)(DMSO)(OH)] a, #

468.06

[M + H]+
[M - OH - DMSO - C8H7N + H]+
[M - OH + H]+
[[V2O3(Sal-L-tryp)2] + H]+
[[V2O3(Sal-L-tryp)2(H2O)] + H]+
[[V2O3(Sal-L-tryp)2(DMSO)2] + H]+

468.60
242.41
451.05
763.68
776.77
918.28

1.67
100.00
48.25
30.06
49.36
3.13

[VO(Sal-L-tryp)(DMSO)(OH)] b, #

468.06

[M + H]+
[N-Ethhymethohcarbthio + H]+
[M - OH + H]+
[M - OH + N-Ethhymethohcarbthio + H]+
[[V2O3(Sal-L-tryp)2 + H]+
[[V2O3(Sal-L-tryp)2( H2O)] + H]+
[[V2O3(Sal-L-tryp)2( DMSO)2] + H]+

470.01
252.26
451.96
702.75
763.22
775.40
916.44

0.50
100.00
2.97
2.15
0.74
1.08
0.75

a - product obtained from compound 1
b - product obtained from compound 3
# - positive mode
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Scheme 9. Proposed species found during ESI MS acquisition of compound 2.
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Scheme 10. Proposed species found during ESI MS acquisition of compound 3.
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Scheme 11. Proposed species found during ESI MS acquisition of compound 4.
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Oxidized products isolated from Compounds 1 and 3. Oxovanadium(IV)
complexes containing N-salicylidene-L-aminoacidatos ligands are readily oxidized to
form vanadium(V) compounds. 60 Our data suggested that compounds 1-4 were readily
oxidized to form vanadium(V) upon aerial oxidation in DMSO. In this study,
however, we will focus on compounds 1 and 3. ESI MS spectra of the products
obtained from the oxidized solutions of compounds 1 and 3 were acquired in both the
positive and negative ion mode of the spectrometer (see Appendix, Figures A19 to
A22). Assignments of spectral peaks (as shown in Table 7) were done using the
spectra obtained in the positive ion mode of the sprectrometer.
As reported by Cavaco et al.,60 coordinated water molecules present in
oxovanadium(IV) complexes, such as [VO(Sal-L-ala)(H2O)], are readily substituted
by solvent molecules such as methanol. Upon substitution of solvent molecules, the
vanadium(V) species formed readily dimerizes to form binuclear species. 60 It is
suggested that our compounds behaved similarly when oxidized. A proposed scheme
showing the aerial oxidation of compounds 1 and 3 in DMSO are shown in Scheme
12.
The ESI MS spectra of the products (obtained from oxidized solutions of
compounds 1 and 3) both exhibited spectral peaks attributed to the [VO(Sal-Ltryp)(DMSO)(OH) + H]+ ion, when analyzed in the positive mode of the spectrometer.
Spectral peaks observed at m/z = 468.60 and m/z = 470.01 were assigned to the [VO(SalL-tryp)(DMSO)(OH) + H]+ ion for products obtained from oxidized solutions of
compounds 1 and compound 3, respectively (see Table 7). The ESI MS spectra acquired
for the oxidized products isolated from compounds 1 and 3 also exhibited peaks
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Scheme 12. Proposed mechanism for the formation of the oxidized compounds in
DMSO.
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attributed to the presence of the vanadium(IV) species, [VO(Sal-L-tryp)(OH)]-, at m/z =
388.94 and m/z = 386.78, respectively. The spectrum acquired for the oxidised product
obtained from compound 3 in DMSO also exhibited a base peak at m/z = 252.26, which
was attributed to the “free” N-Ethhymethohcarbthio ion. This presence of this species
also confirms the formation of [VO(Sal-L-tryp)(DMSO)(OH)] in the proposed
mechanism for the formation of the oxidized compounds in DMSO (Scheme 12).
As mentioned earlier, oxovanadium(IV) complexes are known to form
vanadium(V) binuclear complexes upon oxidation.60 The ESI MS spectra acquired for
both products obtained from oxidized solutions of compounds 1 and 3, both exhibited
several peaks corresponding to the formation of mixed binuclear species in the positive
ion mode of the spectrometer. Peaks assigned to the formation of the binuclear
[V2O3(Sal-L-tryp)2(DMSO)2] species were observed at m/z = 918.28 and m/z = 916.44,
for the oxidized products obtained from compound 1 and compound 3, respectively.
The ESI MS spectrum of the product obtained from the oxidized solution of compound 3
also exhibited a peak at m/z = 702.75. This peak is proposed to be due to the ion formed
when the “free” N-Ethhymethohcarbthio ligand coordinates to the [VO(Sal-Ltryp)(DMSO)(OH)] species via the phenolate moiety of the “free” NEthhymethohcarbthio ligand (see Scheme 12).
FT IR Spectroscopy
Compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. FT IR spectra were
acquired for compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O (see Appendix,
Figures A23-A27) and significant FT IR spectral bands are shown in Table 8 (A). A
general decrease is observed in the (N-H) stretching frequency of the -N1H2 group

78
upon coordination of thiosemicarbazone ligands. Coordination of the respective
“free” thiosemicarbazone ligands to the vanadium(IV) metal center results in a shift in
the the (N-H) stretching frequencies from 3399 cm-1 to 3308 cm -1 for compound 2,
3340 cm-1 to 3306 cm -1 for compound 3, and 3358 cm-1 to 3310 cm -1 for compound 4.
A decrease was also observed in the (N-H) stretching frequencies of the -N2H group
from 3201 cm-1 to 2976 cm-1 for compound 2, 3300 cm-1 to 2970 cm -1 for compound
3, and 3169 cm -1 to 2976 cm -1 for compound 4.
The FT IR spectra of compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O all
exhibited indolic (N-H) stretching frequencies at 3350 cm-1, 3200 cm-1, 3210 cm-1, 3229
cm-1 and 3229 cm-1, respectively. A comparison between the indolic (N-H) stretching
frequency observed in the FT IR spectra of compound 1 and [Zn(Sal-Ltryp)(H2O)].0.25H2O with that of compound 2-4, illustrated a negative shift upon
coordination of the “free” thiosemicarbazone ligand to the metal center.
The FT IR spectra of all complexes exhibited a (V-S) stretching frequencies at
455 cm-1, 454 cm-1, and 455 cm-1 for compounds 2, 3, and 4, respectively. The presence
of (V-S) stretching frequencies in the FT IR spectra of compounds 2-4 confirmed that
the respective ligands were coordinated to the vanadium metal center via the thiocarbonyl
sulphur atom.58 Similar peaks were absent in the FT IR spectra of the “free”
thiosemicarbazone ligands.
Spectral bands observed in the region 1626 to 1615 cm-1 were assigned earlier to
the (C=N) stretching frequency of the thiosemicarbazone ligand.148,152,153,156 Upon
coordination, however, a significant decrease was observed in the (C=N) stretching
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Table 8
FT IR data for the complexes.
(A)

Compounds 1-4 and Zn(Sal-L-tryp)(H2O)].0.25H2O

Compound

Indolic
(NH)
/cm-1

–N1H2
(NH)
/cm-1

N2H
(NH)
/cm-1

1

3478 (m)

-

-

2

3200 (m)

3340
(m),

3

3210 (m)

4
Zn(Sal-Ltryp)(H2O)].
0.25H2O

(B)

(N-N)
/cm-1

(C-O)
/cm-1

/cm

-

1540 (m)

1490 (m)

2976 (w)

1148 (m)

1544 (m)

1491 (m)

3306 (m)

2970 (w)

1154 (m)

1540 (m)

1480 (m)

3229 (m)

3310 (m)

2976 (w)

1149 (m)

1545 (m)

1480 (m)

3405 (m)

-

-

-

1551 (m)

1473 (m)

as

s (COO)
-1

(COO)
/cm-1
1597 (s)
1600 (s)
1600 (s)
1600 (s)
1597 (s)

TSC
(C=N)
/cm-1

Sal-Ltryp
(C=N)
/cm-1

(C=S)
/cm-1

(V-S)
/cm-1

(V=O)
/cm-1

(OH)
/cm-1

-

1600 (m)

-

-

997 (s)

3014
(br)

1624 (m)

1590 (m)

1225 (m), 829 (m)

455 (m)

980 (s)

-

1620 (m)

1580 (m)

1270 (m), 802 (m)

454 (m)

976 (s)

3010
(br)

1624 (m)

1580 (m)

1287 (m), 819 (m)

455 (m)

982 (s)

-

-

1581 (m)

-

-

-

3256
(br)

Oxidized products isolated from compounds 1 and 3

Compound

Indolic
(NH)
/cm-1

(C-O)
/cm-1

/cm

/cm

s (COO)
-1

as (COO)
-1

TSC
(C=N)
/cm-1

Sal-L-tryp
(C=N)
/cm-1

(V=O)
/cm-1

(OH)
/cm-1

(S=O)
/cm-1

a

[VO(Sal-L-tryp)(DMSO)(OH)]

3185 (m)

1551 (m)

1497 (m)

1618 (s)

-

1581 (m)

949 (s)

3194 (br)

1164 (m), 1213 (m)

b

[VO(Sal-L-tryp)(DMSO)(OH)]

3201 (m)

1550 (m)

1497 (m)

1600 (s)

1666 (m)

1590 (m)

946 (s)

3193 (br)

1133 (m), 1157 (m)

a – oxidized product obtained from compound 1
b – oxidized product obtained from compound 3
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frequencies for acetylethTSC (1543 to 1624 cm -1 in compound 4) and NEthylmethocarbthio (1606 to 1620 cm -1 in compound 3). A significant shift in the
(C=N) stretching frequency was not evident in the FT IR spectrum of compound 2.
A decrease in the (C=N) stretching frequency upon coordination of respective
ligands suggested tha the nitrogen atom (belonging to the -C=N moiety) was involved
in the ligation process. 128,147,150,152,183-186
A (C=N) stretching frequency attributed to azomethine moiety present in the
Sal-L-tryp entity of compounds 1-4 were also observed in the respective FT IR spectra. A
comparison of the respective (C=N) stretching frequencies observed in the FT IR
spectra of K[(Sal-L-tryp)] with that of compounds 1-4 and [Zn(Sal-Ltryp)(H2O)].0.25H2O, suggested that this moiety is also in the vicinity of the
vanadium(IV) metal center. Upon coordination of the respective “free”
thiosemicarbazone ligands, a shift was observed in the (C=N) stretching frequencies (of
the Sal-L-tryp moiety) from 1570 cm-1 for K[(Sal-L-tryp)] to 1580 cm-1 for compounds 3
and 4, 1600 cm-1 for compound 1, 1590 cm-1 for compound 2, and 1581cm-1 for [Zn(SalL-tryp)(H2O)].0.25H2O.
Similarly, the involvement of the thiocarbonyl moiety of the
thiosemicarbazone ligands in the ligation process was also inferred based on the
decrease in the (C S) stretching frequencies upon coordination.128,183,184 Medium
intensity spectral bands in the region 841-816 cm-1 were earlier assigned to (C S)
stretching frequency.152,157,158 Upon coordination, a decrease in the order of 12-29
cm-1 was observed in the (C S) stretching frequencies of each complex. The
magnitude of the shift in the (C S) stretching frequencies confirmed that the
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thiosemicarbazone ligands are also coordinated of to the metal center via the neutral
thioamide sulphur.128,147,183 Based on the results presented above, it is evident that the
neutral, bidentate thiosemicarbazone ligands are coordinated to the vanadium(IV)
metal center via the nitrogen atom of the -C=N group and the sulphur tom of the
thiocarbonyl group.128,183
Broad spectral peaks attributed to (OH) stretching frequencies were observed
at 3014 cm -1, 3010 cm -1, and 3256 cm-1 for compounds 1 and 3 and [Zn(Sal-Ltryp)(H2O)].0.25H2O, respectively. The absence of a similar (OH) stretching
frequencies in the FT IR spectra acquired for compounds 2 and 4 confirmed that the
Sal-L-tryp moiety was coordinated to the vanadium(IV) metal center via the phenolate
anion of the respective group. 148,154
All complexes exhibited spectral peaks in the region 997-980 cm-1 attributed
to the (V O) stretching frequencies for typical oxovanadium(IV)
complexes.156,184,187 The (V O) stretching frequencies were observed at 997 cm -1,
980 cm-1, 976 cm-1, and 982 cm -1, for compounds 1, 2, 3, and 4, respectively.
Subsequent to the coordination of the respective thiosemicarbazone ligands to
compound 1, a significant decrease in the (V O) stretching frequency occurred, viz.,
17 cm-1 in compound 2, 21 cm-1 in compound 3, and 15 cm-1 in compound 4.
Oxidized products isolated from Compounds 1 and 3.
FT IR spectroscopic data acquired for the oxidized products are shown in
Table 9 B. Sulphur-containing ligands, such as DMSO, exhibit two potential donor
sites and are therefore capable of coordinating to metal centers via the oxygen or
sulphur atom present in the ligand.188 Oxygen coordination is favored by smaller,
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highly charged metal ions whereas heavier metals are known to coordinate via the
sulphur atom.188-190 According to Cotton et al.,189 [M(DMSO)2Cl2] (M = Pt and Pd)
complexes are known to exhibit two strong spectral signals in the regions (1163 to
1116 cm-1) and (1143 to 1117 cm -1), attributed to the coordination of the DMSO
ligand via the sulphur atom. 188 The FT IR spectra acquired for the oxidized products
obtained from compounds 1 and 3, both exhibited (S O) stretching frequencies
assigned to S-bonded DMSO ligand at 1164 and 1213 cm-1, and 1133 and 1157 cm -1,
respectively.
Subsequent to aerial oxidation of compounds 1 and 3, a decrease was observed
in the indolic (N-H) stretching frequency from 3407 cm-1 for K[(Sal-L-tryp)] to 3185
cm-1 and 3201 cm -1 for the oxidized products obtained from compound 1 and 3,
respectively.
A similar spectral signal attributed to the (C=N) stretching frequency of the
“free” N-Ethylmethocarbthio ligand was also observed in the FT IR spectrum
acquired oxidized product obtained from compound 3. This spectral signal, observed
at 1666 cm-1, was assigned to the (C=N) stretching frequency of the displaced “free”
N-Ethhymethohcarbthio ligand, upon aerial oxidation of compound 3. FT IR
spectroscopic data therefore confirms that the oxidized product consisted of a mixture
of the “free” displaced thiosemicarbazone ligand, as well as [VO(Sal-Ltryp)(DMSO)(OH)].
Spectral signals corresponding to (C=N) stretching frequencies of the Sal-Ltryp moiety were also observed at 1581 cm -1 and 1590 cm -1 for the products obtained
from oxidized solutions of compounds 1 and 3, respectively. The FT IR spectra of
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both oxidzed products also demonstarted an increase in the (V O) stretching
frequency upon aerial oxidation. Comparison of the respective spectra illustrated a
shift in the (V O) from 997 cm -1 to 949 cm-1 for the product obtained from oxidized
compound 1, and from 976 cm -1 to 946 cm -1 for the product obtained from oxidized
compound 3. A broad spectral line attributed to the (OH) stretching frequency was
also observed at 3194 cm-1 and 3193 cm-1 for the products obtained from oxidized
solutions of compounds 1 and compound 3, respectively.
NMR Spectral Studies
NMR spectra were acquired for the oxidized products derived from
compounds 1 and 3 (see Appendix, Figures A29 and A30) using DMSO-d6 as the
solvent. Figure 36 shows the lettering system used for the assignments of protons for
the oxidized complexes (see the experimental section for the lettering in the NMR
data).
O
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Figure 36. Assignments used for NMR data of complexes in the experimental section.
Both 1H NMR spectra acquired for the oxidized products (isolated from compounds 1
and 3) exhibited broad signals (see Appendix, Figures A24 and A25). These broad
signal were suggested to be due to the formation of a paramagnetic vanadium(IV)
species, [VO(Sal-L-tryp)(OH)] -, which was identified by ESI MS as discussed above.
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The resonance signals most useful for determining the binding mode of DMSO
was reported to occur at

= 2.7 ppm for O-bonded DMSO and at

for S-bonded DMSO.147 The absence of a resonance signal at

= 3.0 - 3.6 ppm

= 2.7 ppm suggested that

the DMSO ligand was coordinated via the of sulfur atom and therefore confirms previous
assignments made in the FT IR spectroscopic analysis.147 The NMR spectra of the
oxidized products both exhibited a singlet in the region

= 3.0 to 3.6 ppm: = 3.36 ppm

for the oxidized product isolated from compound 1 and at = 3.34 for the product
isolated from compound 3.
The 1H NMR spectrum acquired for the oxidized product isolated from precursor
3 exhibited resonance signals at = 1.17 ppm and = 3.79 ppm, assigned to the methyl
and methylene protons of the “free” N-Ethhymethohcarbthio ligand, respectively.
Multiplets were also observed in the range = 6.87 - 7.43 ppm in the spectrum acquired
for the oxidized product isolated from precursor 3. These resonance signals were
attributed to the aromatic protons present in the “free” N-Ethhymethohcarbthio ligand
and the oxidized complex.
The 1H NMR spectrum acquired for the oxidized product isolated from compound
1 exhibited resonance signals in the region = 7.06 to 7.52 ppm, which were assigned to
aromatic protons of the oxidized product. Resonance signals attributed azomethine proton
of the indole ring present in the L-tryptophan moiety were also observed at in the region
= 7.82 to 8.09 ppm, and = 7.06 to 10.43 ppm, for the oxidized products isolated from
compound 1 and compound 3, respectively. In the 1H NMR spectrum acquired for the
oxidized product isolated from compound 3, the previously mentioned resonance signal
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was suggested to be overlapped with the signal attributed to the N(2)-H proton of the
“free” N-Ethhymethohcarbthio ligand.
UV-Visible and Fluorescence Spectroscopic Studies of Compound 1-4
UV-visible spectral data were acquired for compounds 1-4 using DMSO as
solvent. The respective UV-visible spectra acquired for compounds 1-4 are shown in
figures 36-39 (See Appendix, Figures A31-A33), and the assignments are shown in
Table 9. The UV-Visible spectra acquired for compounds 2-4 all exhibited charge
transfer bands in the region 266-292 nm, assigned to π→π* transitions associated
with the thioamide moiety.

152,154

These spectral bands were observed at 266 nm and

292 nm (shoulder) for compound 2, at 270 nm and 288 nm (both as shoulders) for
compound 3, and at 276 nm for compound 4. Previous spectroscopic studies has
proven that charge transfer bands attributed to n→π* transitions of aromatic rings
usually exist in the region 316-352 nm.152,154,184,191,192 Similar spectral bands were
also observed in the UV-Vis spectra of compounds 2-4. The respective bands were
observed as a shoulder at 316 nm for compound 2, at 330 nm for compound 3, and
352 nm for compound 4.
According to Cavaco et al.,60 oxovanadium(IV) complexes derived from
salicylaldehyde ligands are known to exhibit a low-energy spectral band around 375
nm, attributed to π→π* transitions associated with the azomethine chromophore. 60
Similar spectral bands were also observed at 388 nm for compound 2, as a shoulder at
390 nm for compound 3 and hidden beneath the n→π* transition for compound 4. The
UV-Visible spectra acquired for compounds 1-4 all exhibited spectral bands in the
region 550-558 nm, attributed to p→d LMCT transitions (where p represents the lone
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Figure 37. A UV-visible spectrum of compound 1 in DMSO.

Figure 38. A UV-visible spectrum of compound 2 in DMSO.
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Figure 39. A UV-visible spectrum of compound 3 in DMSO.

Figure 40. A UV-visible spectrum of compound 4 in DMSO.
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Table 9
UV-visible spectral data for compounds 1-4.

Complex

1

2

3

4

/nm

/M-1cm-1

Assignments

558
758

44
27

LMCT (p → d transition)
d → d transition

266
292 (sh)
316 (sh)
388
550
592 (sh)
756

74835
17954
10046
15013
54
45
28

π → π* (thioamide moiety)
π → π* (thioamide moiety)
n → π* (aromatic rings)
π → π* (azomethine chromophore)
LMCT (p → d transition)
d → d transition
d → d transition

270 (sh)
288 (sh)
330
390 (sh)
620

10984
13874
24837
18250
852

π → π* (thioamide moiety)
π → π* (thioamide moiety)
n → π* (aromatic rings)
π → π* (azomethine chromophore)
d → d transition

276
352
558
590 (sh)
756

21969
14227
80
70
38

π → π* (thioamide moiety)
n → π* (aromatic rings)
LMCT (p → d transition)
d → d transition
d → d transition

pair of electrons on the phenolato oxygen, and d represents the 3d orbitals of the
vanadium metal center).193,194 Similar spectral bands were observed at 558 nm for
compound 1, 550 nm for compound 2, and 558 nm for compound 4. A similar spectral
band was absent in the UV-Visible spectrum acquired for compound 3 since it is believed
to be hidden under the spectral band assigned to d→d transitions.

89
According to Pessoa et al., the UV-Visible spectral bands observed in the region
756-758 nm are attributed to d-d transitions of the metal center.187 In our case, similar
spectral bands were observed at 758 nm for compound 1 and at 756 nm for compounds 2
and 4. Spectral bands assigned to d→d transitions also appeared as shoulders (of the
much stronger LMCT band in the region 550-558 nm) at 592 nm and 590 nm for
compounds 2 and 4, respectively.
Fluorescence spectral data were acquired for compounds 2-4 in DMSO (see
appendix, Figures A26-A28). Compounds 2, 3, and 4 were excited at 400, 330, and
340 nm, respectively. The highest fluorescence intensity was observed in the
fluorescence spectrum of compound 2 due to the presence of an anthracene moiety in
the MEATSC ligand while compounds 3 and 4 produced the lower intensities.
Electrochemical Studies
Compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. CV and square wave
voltammograms were acquired for Compound 1-4 and [Zn(Sal-Ltryp)(H2O)].0.25H2O as shown in figures 40 and 41 (see Appendix, Figures A34 and
A35). The data collected from electrochemical studies are shown in Table 10. The
Zn(II) metal center is known to be redox inactive. 195 Electrochemical data acquired
for [Zn(Sal-L-tryp)(H2O)].0.25H2O was therefore used to confirm the electrochemical
data due to metal-based electron transfer in compounds 1-4.
An irreversible anodic redox peak attributed to the oxidation of the L-
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Figure 41. A cyclic voltammogram of a 1.0 mM solution of [Zn(Sal-Ltryp)(H2O)].0.25H2O in DMSO. Electrodes: platinum working electrode, platinum
auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile)
reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1.

Figure 42. Cyclic voltammograms of 1.0 mM solutions of compounds 1-4 in DMSO.
Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. Supporting electrolyte =
0.1 M TBAP. Scan rate = 100 mV s-1.
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Table 10
Electrochemical data of 1.0 mM solutions of compounds 1-4, product isolated from
oxidized compound 1, and [Zn(Sal-L-tryp)(H2O)].0.25H2O in DMSO.
A) Compounds 1-4
Species

E/V

Assignment

1

Epa
Epa
Epa
Epa
Epc
Epc

=
=
=
=
=
=

+0.71
+0.22
-0.78
-1.28
-0.88
-1.57

L-tryp0/+
VIV/V
VIII/IV
VIV/III
L-tryp+/0

2

Epa
Epa
Epa
Epa
Epa
Epc
Epc

=
=
=
=
=
=
=

+0.87
+0.73
+0.21
-0.78
-1.24
-0.89
-1.57

Oxidation of anthracene moiety
L-tryp0/+
VIV/V
VIII/IV
CH2-NH/ HC=N
VIV/III
L-tryp+/0

3

Epa
Epa
Epa
Epa
Epa
Epa
Epa
Epc
Epc
Epc
Epc

=
=
=
=
=
=
=
=
=
=
=

+0.81
+0.64
+0.43
+0.21
-0.16
-1.07
-1.36
-0.34
-0.88
-1.17
-1.65

L-tryp0/+
Oxidation of phenolate in vanillin moiety
VIV/V
VIII/IV
CH2-NH/ HC=N
VIV/III
L-tryp+/0
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Table 10 (continued).

Species

E/V

4

Epa
Epa
Epa
Epa
Epa
Epa
Epa
Epc
Epc
Epc
Epc

B)

Assignment

=
=
=
=
=
=
=
=
=
=
=

+0.82
+0.66
+0.21
-0.12
-1.07
-1.31
-1.67
-0.68
-0.92
-1.13
-1.51

L-tryp0/+
VIV/V
VIII/IV
CH2-NH/ HC=N
VIV/III
L-tryp+/0

Oxidized product obtained from compound 1 and [Zn(Sal-Ltryp)(H2O)].0.25H2O.

Species

E/V

Oxidized Compound 1

Epa
Epa
Epa
Epa
Epa
Epa
Epc
Epc
Epc
Epc
Epc
Epc

Assignment

=
=
=
=
=
=
=
=
=
=
=
=

+0.66
+0.22
-0.12
-1.06
-1.39
-1.66
-0.17
-0.48
-0.96
-1.15
-1.30
-1.50

L-tryp0/+
VIV/V
VIII/IV
VIV/III
VV/IV
L-tryp+/0
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Table 10 (continued).

Species

E/V

[Zn(Sal-L-tryp)(H2O)].0.25 H2O

Epa
Epa
Epa
Epa
Epc
Epc
Epc

Assignment

=
=
=
=
=
=
=

+0.71
+0.59
-0.67
-1.34
-0.84
-1.30
-1.59

L-tryp0/+
PhO-/.
-

L-tryp+/0

Note. Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1.

tryptophan moiety of the Schiff base ligand (salicylaldehyde) was observed in the CV
of each complex. Upon coordintion of the Schiff base ligand (salicylaldehyde moiety)
to the respective metal center, a decrease in the redox potential attributed to the
oxidation of the L-tryptophan moiety was generally observed. This redox potential
decreased from +0.75 V in K[(Sal-L-tryp)] to +0.71 V for [Zn(Sal-Ltryp)(H2O)].0.25H2O and compound 1, to +0.73 V for compound 2, to +0.64 V for
compound 3, and to +0.66 V for compound 4. The respective aniodic redox peaks
were also confirmed using square wave voltammetry. The square voltammograms
(see Appendix, Figures A38 and A39) of all complexes exhibited anodic redox peaks
at +0.70 V for [Zn(Sal-L-tryp)(H2O)].0.25H2O, at +0.67 V for compounds 1, 2, and 3,
and at +0.62 V for compound 4. These redox peaks were all attributed to the oxidation
of the L-tryptophan moiety.
The CV acquired for [VO(salen)] exhibited an irreversible anodic redox peak
at +0.50 V, attributed to the V(IV)/V(V) redox couple as reported by Kianfar and
Mohebbi.196 According to Maia et al.,197 electrochemical data acquired for V(IV)

94
complexes were also shown to exhibit irreversible anodic redox peaks in the region
+0.60 V to +0.65 V, attributed to the V(IV)/V(V) redox couple. 197 Similar redox
peaks attributed to the V(IV)/V(V) redox couple were also observed in the CV’s
acquired for our complexes. The irreversible anodic redox peaks attributed to the
V(IV)/V(V) redox couple were observed at +0.22 V for compound 1 and at +0.21 V
for compounds 2-4. Redox peaks attributed to the V(IV)/V(V) redox couple were
observed at +0.18 V for compounds 1 and 3 and at +0.17 V in the square wave
voltammograms of compounds 2 and 4.
CV acquired for oxovanadium(IV) complexes are also known to display
cathodic quasi-reversible voltammetric responses attributed to the V(IV)/V(III) redox
couple in the potential range -0.9 V to -1.3 V.191 In our case, simiar cathodic quasireversible redox peaks were observed at -0.88 V, -0.89 V, -0.88 V and -0.92 for
compounds 1, 2, 3, and 4, respectively. The corresponding anodic quasi-reversible
redox peak were observed at -0.78 V for compounds 1 and 2 and at -1.07 V
compounds 3 and 4. All other cathodic peaks observed in the voltammograms
acquired for each complex were assigned to the reduction of cation radicals
Oxidized products isolated from Compounds 1. The representative CV and
square wave voltammogram acquired for the product isolated from the oxidized
solution of compound 1 is shown in figures 43 and 44. Products obtained from
oxidized DMSO solutions of compounds 2-4 are proposed to exhibit similar
electrochemical properties.
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Figure 43. A cyclic voltammogram of a 1.0 mM solution of the oxidized product
isolated from compound 1 in DMSO. Electrodes: platinum working electrode, platinum
auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile)
reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1.

Figure 44. A square wave voltammogram: The oxidation of a 1.0 mM solution of the
oxidized product isolated from compound 1 in DMSO. Electrodes: platinum working
electrode, platinum auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Initial potential =
0 V, final potential = +1.0 V, step E = 4 mV, S.W. amplitude = 25 mV, S.W. frequency =
15 Hz, filter = 100 Hz, and quiet time = 2 s.
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Anodic redox peaks attributed to the oxidation of the L-tryptophan moiety, were
observed at +0.66 V and at +0.63 V in the CV and square wave voltammogram (of the
product isolated from the oxidized solution of compound 1), respectively. Redox
couples were observed at +0.22 V and 0.18 V in the CV and square wave
voltammogram, respectively. The observance of a redox peak corresponding to the
V(IV)/V(V) redox couple suggested that the product isolated from the oxidized
solution of compound 1 was actually a mixture V(IV) and V(V) species. The CV of
this oxidized product also exhibited a quasi-reversible redox wave (Epc = -0.96 V
and Epa = -1.06 V) attributed to the V(IV)/V(III) redox couple. 191
In vitro Studies
The data aquired from in vitro studies are presented in Table 11. The aim of
these in vitro studies is to evaluate the antiproliferative activity of compounds 1-4
against colon cancer cell lines (HTC-116, Caco-2, and HT-29) and to compare the
anti-proliferative activity with that of one non-cancerous colon cell line (CCD18-Co).
Colorimetric assay (MTS assay), a technique that measures mitochondrial
dehydrogenase activity as an indication of cell viability was used to evaluate the
cytotoxicity of compounds 2-4 on three different cancer colon cell lines (HCT116,
Caco-2 and HT-29). The effects of the compounds on the viability of these cells were
evaluated after continuous incubation (24, 48, and 72 hours).
A comparison between the growth inhibition effect of the respective
compounds against non-cancerous colonic myofibroblasts CCD-18Co cells and cancer
colon cell lines were investigated. The results indicated a large difference in the
inhibition of cell proliferation between cancer lines and the non-cancerous CCD-18Co
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Table 11
Anti-proliferative effects of compounds 2-4, cisplatin, and etoposide on different cells
lines after 24, 48 and 72 hours treatment.

24 hrs

HT-29
48 hrs

24 hrs

Caco-2
48 hrs

IC50/ M

IC50/ M

IC50/ M

IC50/ M

IC50/ M

IC50/ M

2

277.1±10.2

239.6±7.9

100.3±5.1

277.1±16.3

147.1±10.8

87.9±0.5

281.6±14.4

152.5±12.7

128.6±10.7

169.6±15.
1
82.4±9.6

166.2±15.3

85.4±14.0

84.7±1.9

80.6±1.6

69.1±3.2

349.1±19.
5
367.0±21.
5
242.1±25.
1
32.0±1.6

3

244.2±8.8

4
Cisplatin

22.8±1.5

17.9±1.8

Etoposide 19.2±0.8

17.3±1.9

15.8±2.4

47.6±0.8

46.2±1.9

40.9±1.5

72 hrs

24 hrs

Species

Species

24 hrs

HCT-116
48 hrs

72 hrs

47.8±5.5

CCD-18Co
48 hrs

72 hrs

72 hrs

IC50/ M

IC50/ M

IC50/ M

IC50/ M

IC50/ M

IC50/ M

2

203.4±7.7

181.3±9.2

115.0±6.5

495.6±23.5

339.2±16.7

208.0±11.9

3

227.4±6.8

192.7±11.6

110.3±10.1

490.6±27.6

329.5±15.4

203.6±12.5

4

161.3±4.6

134.9±3.9

89.5±14.5

382.7±21.9

246.2±11.4

152.2±12.0

Cisplatin

53.8±2.1

49.7±1.3

41.0±2.7

83.0±1.1

72.0±1.5

64.1±1.6

Etoposide 40.8±0.5

36.2±2.0

38.4±1.2

82.5±3.1

79.2±1.2

73.2±1.9

cells. The growth inhibition effect of the respective compounds were shown to be
time dependent as shown in Table 11.
Compounds 2-4 have been shown to time-dependently decrease cell viability
of HCT-116, Caco-2, and more potently, in HT-29 cells (Table 11). While compounds
2 and 3 showed similar activities in both cancer cell lines, compound 4 was shown to
be the most active of the three compounds tested. A plot of percentage cell viability
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versus concentration of compound 4 against the HT-29 cancer cell line were plotted
as shown in Figure 45 while the IC50 values for inhibition of cell proliferation for
compounds 2-4. After 72 hours, the IC 50 values for compounds 2 and 3 were generally
around 100 M concentration. Although our compounds did not exhibit better
efficacy against any of the cancer cell lines when compared to etoposide, compound 4
was shown to have a better efficacy on the HT-29 cancer cell line when compared to
cisplatin (Table 11).
The possibility of cytotoxic selectivity towards colon cancer cells is suggested
since all three compounds exhibited less inhibitory effects in human normal CCD -

Figure 45. MTT cell proliferation assay of compound 4 against the HT-29 cancer cell
line.
18Co cells. The IC50 values obtained for CCD-18Co were observed to be 3-fold and 2fold than HT-29 and Caco-2 and HCT-116, respectively. The cytotoxic selectivity of
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cisplatin (a positive control) towards the cancer colon cells (except on Caco-2 cells) was
observed to be slightly lower than our synthesized compounds (Table 11). Cisplatin was
previously reported to inhibit cell proliferation by about 70% in both cell lines (cancer
and normal colon cells).198 Overall, due to the fact that compounds 2-4 had no effect on
non-cancerous cells but exhibited properties of potential growth suppressors of cancer
cells, these compounds are proposed to be potential chemotherapeutic agents.
Although metal complexes are currently being investigated as probes and
therapeutics, the various pathways and uptake mechanisms for metal complexes into
cells are are sparse in literature. A review of the cellular accumulation of cisplatin
has recently been reported. 199,200 Platinum-containing drugs are capable of entering
the cell by passive diffusion, by organic cation transporters, by the copper transporter
Ctr1, and possibly by endocytosis. 200 Ruthenium(II) complex containing lipophilic
cations, for example the lipophilic 4,7-diphenyl-1,10-phenanthroline ligand, has been
shown to passively diffuse across the plasma membrane in a membrane-potential
dependent manner.200 The excellent efficacy of the ruthenium(II) complexes with
thiosemicarbazones as reported in a study by Beckford and co-workers128 is also
suggested to be due to the lipophilic nature of the respective complexes. Similarly,
lipophilic cations, such as [(bpy)2Ru(thiosemicarbazone)](PF 6)2 and
[(phen)2Ru(thiosemicarbazone)](PF 6)2 (where thiosemicarbazone = 9anthraldehydethiosemicarbazone, 9-anthraldehyde-N(4)-methylthiosemicarbazone,
and 9-anthraldehyde-N(4)-ethylthiosemicarbazone),128 are also observed to have
better efficacies against HT-29 and HCT-116 cell lines versus our neutral
vanadium(IV) complexes for similar reasons.
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In order to accurately conclude, a systematic study of ruthenium(II) complexes
and compounds 2-4, all under the same conditions, is needed. Apart from such a
study, a more detailed emphasis will be placed on the methods used to examine
cellular accumulations in order to identify the mechanism(s) of uptake, and to monitor
possible efflux compounds 2-4, and their analogues in the near future. 201
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CHAPTER IV
CONCLUSIONS AND FUTURE WORK
Conclusions
Two novel thiosemicarbazone ligands, MeATSC and N-Ethhymethohcarbthio
were successfully synthesized and characterized. A reduced Schiff base and K[Sal-Ltryp)] ligand was also synthesized and characterized. Each thiosemicarbazone ligand was
then coordinated to [VO(Sal-L-tryp)] (1) to form three novel V(IV) complexes.
Thiosemicarbazones are known to exhibit thione-thiol tautomerism and can coordinate to
metal centers either as a neutral (thione) or as a mono-anionic (thiolate) ligand. Due to
the absence of a ((S-H) spectral band in the FT IR spectra, the ligands were said to exist
as neutral (thione) ligands.
Upon aerial oxidation, DMSO solutions of compounds 1-4 were readily oxidized
to form V(V) species. All compounds are believed to behave similarly; hence, for this
study, we focused on compounds 1 and 3 only. ESI MS data was used to identify the
species formed in solution upon oxidation. The proposed mechanism (Scheme 14)
suggests that the ligands are first substituted by DMSO solvent molecules followed by
the dimerization of the solvated complexes to form binuclear species.
In this study, all four V(IV) compounds were shown to exhibit anti-cancer effects
against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. A comparative antiproliferative study on non-cancerous colonic myofibrolasts, CCD18-Co, indicated that
our novel compounds had no effect on these non-cancerous colorectal cells. The novel
V(IV) compounds were also shown to exhibit cytotoxic selectivity towards colon cancer
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cells. Cytotoxic selectivity was evident since compounds 2-3 exhibited less inhibitory
effects in human non-cancerous CCD-18Co cells.
Overall, although compounds 1-4 are relatively unstable, compounds 2-3
exhibited interesting anti-proliferative activity on colon cancer cells. Due to existence of
several species in solution (upon oxidation), the identity of the active species still remains
unclear. A thorough investigation is therefore needed in order to identify the active
species responsible for anti-proliferative activity. We are therefore suggesting that these
compounds might be effective as chemotherapeutic agents.
Future Work
The synthesis and characterization of these novel thiosemicarbazone ligands and
V(IV) compounds has paved the way for a series of interesting research with similar
compounds. These compounds were shown to exhibit anti-cancer activity against colon
cancer cell lines. This area of research can be expanded by synthesizing a series of
similar V(IV) complexes containing varying thiosemicarbazone ligands. It is also
important to investigate the effect of varying thiosemicarbazone ligands on the stability
of the respective complexes.
During this study compounds 1-4 were shown to be readily oxidized to V(V)
species upon aerial oxidation. The question as to the identity of the species solely
responsible for antiproliferative activity is therefore asked. ESI MS data has provided
information allowing us to formulate a proposed mechanism for the identity of the
species formed upon oxidation. An in depth study is therefore needed in order to confirm
the identity of the oxidized species and to study the relative stability and anti-proliferative
effects of such oxidized species.
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APPENDIX A
A MASS SPECTRUM OF THE REDUCED SCHIFF BASE (2-(2HYDROXYBENZYLAMINO)-3-(1H-INDOL-3-YL)PROPANOIC ACID) IN THE
POSITIVE MODE
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APPENDIX B
A MASS SPECTRUM OF K[(Sal-L-tryp)] IN THE POSITIVE MODE
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APPENDIX C
AN FT IR SPECTRUM OF MEATSC
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APPENDIX D
AN FT IR SPECTRUM OF N-ETHHYMETHOHCARBTHIO

107
APPENDIX E
AN FT IR SPECTRUM OF ACETYLETHTSC
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APPENDIX F
FT IR SPECTRUM OF THE REDUCED SCHIFF BASE
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APPENDIX G
AN FT IR SPECTRUM OF K[(Sal-L-tryp)]
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APPENDIX H
A 1H NMR SPECTRUM OF THE REDUCED SCHIFF BASE
IN NAOD/D2O (PH = 9.0)
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APPENDIX I
A 1H NMR SPECTRUM OF K[(Sal-L-tryp)] IN DMSO-d6
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APPENDIX J
A 13C NMR SPECTRUM OF THE REDUCED SCHIFF
BASE IN NAOD/D2O (PH = 9.0)
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APPENDIX K
A 13C NMR SPECTRUM OF K[(Sal-L-tryp)] IN DMSO-D6
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APPENDIX L
A 13C NMR SPECTRUM OF N-ETHHYMETHOHCARBTHIO
IN DMSO-d6
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APPENDIX M
A SQUARE WAVE VOLTAMMOGRAM. THE OXIDATION OF A 1.0 MM
SOLUTION OF K[(Sal-L-tryp)] IN DMSO. ELECTRODES: PLATINUM WORKING
ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag+ (0.01 M AgNO3
AND 0.10 M TBAP IN ACETONITRILE) REFERENCE ELECTRODE. SUPPORTING
ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL = 0 V, FINAL POTENTIAL =
+1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, S.W. FREQUENCY = 15 Hz,
filter = 100 Hz, AND QUIET TIME = 2 s
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APPENDIX N
SQUARE WAVE VOLTAMMOGRAMS: THE OXIDATION OF 1.0 MM
SOLUTIONS OF THIOSEMICARBAZONE LIGANDS IN DMSO. ELECTRODES:
PLATINUM WORKING ELECTRODE, PLATINUM AUXILIARY ELECTRODE
AND Ag/Ag+ (0.01 M AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE
ELECTRODE. SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL
= 0 V, FINAL POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV,
S.W. FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s
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APPENDIX O
A MASS SPECTRUM OF COMPOUND 2 IN THE POSITIVE MODE
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APPENDIX P
A MASS SPECTRUM OF COMPOUND 3 IN THE NEGATIVE MODE
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APPENDIX Q
A MASS SPECTRUM OF COMPOUND 4 IN THE POSITIVE MODE
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APPENDIX R
A MASS SPECTRUM OF [Zn(Sal-L-tryp)(H2O)].0.25H2O IN THE POSITIVE MODE
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APPENDIX S
A MASS SPECTRUM OF OXIDISED PRODUCT ISOLATED FROM COMPOUND 1
IN THE POSITIVE MODE
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APPENDIX T
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 1
IN THE NEGATIVE MODE
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APPENDIX U
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 3
IN THE POSITIVE MODE
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APPENDIX V
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 3
IN THE NEGATIVE MODE
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APPENDIX W
AN FT IR SPECTRUM OF COMPOUND
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APPENDIX X
AN FT IR SPECTRUM OF COMPOUND 2
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APPENDIX Y
AN FT IR SPECTRUM OF COMPOUND 3
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APPENDIX Z
AN FT IR SPECTRUM OF COMPOUND 4
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APPENDIX AA
AN FT IR SPECTRUM OF [Zn(Sal-L-tryp)(H2O)].0.25H2O
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APPENDIX BB
A 1H NMR SPECTRUM OF [Zn(Sal-L-tryp)(H2O)].0.25H2O
IN DMSO-d6
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APPENDIX CC
A 1H NMR SPECTRUM OF THE OXIDIZED PRODUCT
OBTAINED FROM COMPOUND 1 IN DMSO-d6
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APPENDIX DD
A 1H NMR SPECTRUM OF THE OXIDIZED COMPLEX
DERIVED FROM COMPOUND 3 IN DMSO-d6
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APPENDIX EE
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF
COMPOUND 2 IN DMSO. EXCITATION WAVELENGTH = 400 nm

APPENDIX FF
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF
COMPOUND 3 IN DMSO. EXCITATION WAVELENGTH = 330 nm

APPENDIX GG
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF
COMPOUND 4 IN DMSO. EXCITATION WAVELENGTH = 340 nm

APPENDIX HH
SQUARE WAVE VOLTAMMOGRAMS: THE OXIDATION OF 1.0 mM
SOLUTIONS COMPOUNDS 1-4 IN DMSO. ELECTRODES: PLATINUM WORKING
ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag+ (0.01 M
AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE ELECTRODE.
SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL = 0 V, FINAL
POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, S.W.
FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s

APPENDIX II
A SQUARE WAVE VOLTAMMOGRAM: THE OXIDATION OF A 1.0 MM
SOLUTION [Zn(Sal-L-tryp)(H2O)].0.25H2O IN DMSO. ELECTRODES: PLATINUM
WORKING ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag+
(0.01 M AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE
ELECTRODE. SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL
= 0 V, FINAL POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV,
S.W. FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s

APPENDIX JJ
ATOMIC COORDINATES (x 104) AND EQUIVALENT ISOTROPIC
DISPLACEMENT PARAMETERS (A2 x 103) FOR VENKAT35. U(eq) IS DEFINED
AS ONE THIRD OF THE TRACE OF THE ORTHOGONALIZED Uij TENSOR
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
S(1)
7608(1)
4402(1)
4836(1)
26(1)
S(2)
3123(1)
4067(1)
7194(1)
23(1)
N(1)
5081(1)
3382(1)
6207(1)
20(1)
N(2)
6001(1)
3320(1)
5703(1)
21(1)
N(3)
6006(1)
5421(1)
5737(1)
20(1)
N(4)
3033(2)
1718(1)
7328(1)
30(1)
C(1)
6484(2)
4402(2)
5460(1)
19(1)
C(2)
4599(2)
2389(2)
6452(1)
24(1)
C(3)
3608(2)
2598(2)
6982(1)
23(1)
C(4)
2174(2)
2220(2)
7788(1)
31(1)
C(5)
2091(2)
3456(2)
7789(1)
27(1)
C(6)
4934(2)
1099(2)
6252(1)
41(1)
C(7)
6390(2)
6658(2)
5541(1)
23(1)
C(8)
5569(2)
7599(2)
5915(1)
27(1)
________________________________________________________________

APPENDIX KK
BOND LENGTHS [Å] AND ANGLES [°] FOR VENKAT35
_____________________________________________________________
S(1)-C(1)
S(2)-C(5)
S(2)-C(3)
N(1)-C(2)
N(1)-N(2)
N(2)-C(1)
N(2)-H(2N)
N(3)-C(1)
N(3)-C(7)
N(3)-H(3N)
N(4)-C(3)
N(4)-C(4)
C(2)-C(3)
C(2)-C(6)
C(4)-C(5)
C(4)-H(4)
C(5)-H(5)
C(6)-H(6A)
C(6)-H(6B)
C(6)-H(6C)
C(7)-C(8)
C(7)-H(7A)
C(7)-H(7B)
C(8)-H(8A)
C(8)-H(8B)
C(8)-H(8C)
C(5)-S(2)-C(3)
C(2)-N(1)-N(2)
C(1)-N(2)-N(1)
C(1)-N(2)-H(2N)
N(1)-N(2)-H(2N)
C(1)-N(3)-C(7)
C(1)-N(3)-H(3N)
C(7)-N(3)-H(3N)
C(3)-N(4)-C(4)
N(3)-C(1)-N(2)
N(3)-C(1)-S(1)
N(2)-C(1)-S(1)
N(1)-C(2)-C(3)

1.6814(16)
1.7094(17)
1.7282(17)
1.284(2)
1.3691(18)
1.366(2)
0.86(2)
1.329(2)
1.457(2)
0.81(2)
1.312(2)
1.376(2)
1.474(2)
1.498(2)
1.349(3)
0.9500
0.9500
0.9800
0.9800
0.9800
1.521(2)
0.9900
0.9900
0.9800
0.9800
0.9800
89.03(8)
119.74(14)
117.46(13)
118.7(13)
123.5(13)
124.42(14)
117.4(15)
118.1(15)
109.59(15)
116.37(14)
123.34(12)
120.29(12)
113.65(14)

N(1)-C(2)-C(6)
127.15(15)
C(3)-C(2)-C(6)
119.19(14)
N(4)-C(3)-C(2)
124.04(15)
N(4)-C(3)-S(2)
114.99(12)
C(2)-C(3)-S(2)
120.97(12)
C(5)-C(4)-N(4)
116.11(16)
C(5)-C(4)-H(4)
121.9
N(4)-C(4)-H(4)
121.9
C(4)-C(5)-S(2)
110.27(13)
C(4)-C(5)-H(5)
124.9
S(2)-C(5)-H(5)
124.9
C(2)-C(6)-H(6A)
109.5
C(2)-C(6)-H(6B)
109.5
H(6A)-C(6)-H(6B)
109.5
C(2)-C(6)-H(6C)
109.5
H(6A)-C(6)-H(6C)
109.5
H(6B)-C(6)-H(6C)
109.5
N(3)-C(7)-C(8)
110.14(14)
N(3)-C(7)-H(7A)
109.6
C(8)-C(7)-H(7A)
109.6
N(3)-C(7)-H(7B)
109.6
C(8)-C(7)-H(7B)
109.6
H(7A)-C(7)-H(7B)
108.1
C(7)-C(8)-H(8A)
109.5
C(7)-C(8)-H(8B)
109.5
H(8A)-C(8)-H(8B)
109.5
C(7)-C(8)-H(8C)
109.5
H(8A)-C(8)-H(8C)
109.5
H(8B)-C(8)-H(8C)
109.5
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:

APPENDIX LL
ANISOTROPIC DISPLACEMENT PARAMETERS (A2 x 103) FOR VENKAT35. THE
ANISOTROPIC DISPLACEMENT FACTOR EXPONENT TAKES THE FORM: -2
[ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]
__________________________________________________________________
U11
U22
U33
U23
U13
U12
__________________________________________________________________
S(1) 25(1) 18(1)
37(1)
3(1) 18(1)
0(1)
S(2) 30(1) 14(1)
28(1)
1(1) 13(1)
1(1)
N(1) 23(1) 18(1)
21(1)
1(1)
9(1)
-1(1)
N(2) 24(1) 14(1)
24(1)
-1(1)
12(1)
0(1)
N(3) 20(1) 16(1)
25(1)
2(1) 10(1)
-2(1)
N(4) 38(1) 17(1)
37(1)
1(1) 23(1)
0(1)
C(1) 17(1) 18(1)
22(1)
1(1)
3(1)
-1(1)
C(2) 30(1) 16(1)
27(1)
-1(1)
13(1)
0(1)
C(3) 29(1) 13(1)
28(1)
0(1) 13(1)
1(1)
C(4) 39(1) 20(1)
37(1)
2(1) 25(1)
0(1)
C(5) 32(1) 20(1)
30(1)
-2(1)
17(1)
3(1)
C(6) 52(1) 16(1)
58(1)
-2(1)
42(1) -3(1)
C(7) 20(1) 15(1)
33(1)
2(1)
8(1) -1(1)
C(8) 27(1) 17(1)
38(1)
1(1)
9(1)
0(1)
_________________________________________________________________

2

APPENDIX MM
HYDROGEN COORDINATES (x 104) AND ISOTROPIC DISPLACEMENT
PARAMETERS (A^2 x 10^3) FOR VENKAT35
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
H(2N)
6339(19) 2640(20) 5564(10) 25
H(3N)
5438(19) 5345(19) 6017(10) 24
H(4)
1668
1725
8088
38
H(5)
1538
3919
8079
33
H(6A)
4809
992
5737
62
H(6B)
4381
525
6503
62
H(6C)
5830
936
6386
62
H(7A)
6294
6763
5018
27
H(7B)
7302
6787
5678
27
H(8A)
4669
7479
5772
41
H(8B)
5839
8427
5783
41
H(8C)
5670
7495
6433
41
_____________________________________________________________
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